

=> fil hcaplus
 FILE 'HCAPLUS' ENTERED AT 10:40:43 ON 13 JUN 2001
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 13 Jun 2001 VOL 134 ISS 25
 FILE LAST UPDATED: 12 Jun 2001 (20010612/ED)

- This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=> d l126 all tot

L126 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2001 ACS

AN 1999:511030 HCAPLUS

DN 131:161631

TI Medicine for treating **apoptosis** dysfunction containing **oligosaccharides**

IN Yvin, Jean-claude; Cruz, Florence; Descamps, Valerie; Richard, Christophe; Thibal, Vesna; Arrigo, Patrick; Cloarec, Bernard

PA Laboratoires Goemar S.A., Fr.

SO PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DT Patent

LA French

IC ICM A61K031-70

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9939718	A1	19990812	WO 1999-FR229	19990203 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2774289	A1	19990806	FR 1998-1237	19980203 <--
	AU 9921710	A1	19990823	AU 1999-21710	19990203 <--
	EP 1052996	A1	20001122	EP 1999-901702	19990203 <--
	R: DE, ES, FR, GB, GR, IT, NL, PT				
PRAI	FR 1998-1237	A	19980203 <--		
	WO 1999-FR229	W	19990203 <--		
AB	The invention concerns a medicine comprising, as active principle, an				

efficient quantity of at least an **oligosaccharide** substance capable of modulating **apoptosis** dysfunction and optionally comprising, on at least some of its unit motifs, at least a substituent of the group comprising sulfate, Me and acetyl groups, the substance being selected from the group comprising: **oligosaccharides** derived by enzymic or chem. process from polymer groups including **.beta. 1-3 glucans** optionally comprising **.beta. 1-6** branches; and **oligosaccharides** derived by enzymic or chem. process from **sulfated galactans**, in particular **carrageenan, agar** and **porphyrins**. Iotacarrageenan was incubated with iotacarrageenase at 45-50.degree. and the hydrolyzed products was ultrafiltered. The efficacy of the above product in prevention of **apoptosis** induced by Fas ligand or anti-Fas receptor antibody was shown.

ST **apoptosis inhibitor oligosaccharide**
carrageenan

IT **Apoptosis**
 (inhibitors; medicine for treating **apoptosis** dysfunction contg. **oligosaccharides**)

IT **Oligosaccharides**, biological studies
 Polymers, biological studies
 RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 (medicine for treating **apoptosis** dysfunction contg. **oligosaccharides**)

IT Antibodies
Fas ligand
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (medicine for treating **apoptosis** dysfunction contg. **oligosaccharides**)

IT **Fas antigen**
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (medicine for treating **apoptosis** dysfunction contg. **oligosaccharides**)

IT 9000-07-1, Carrageenan 9002-18-0, Agar
 9062-07-1, .iota.-Carrageenan
 11016-36-7D, Porphyrin, derivs. 39475-64-4,
 Galactan sulfate 237069-70-4, .iota.-
 Neocarratetraose 237069-74-8, .iota.-
 Neocarrahexaose 237069-76-0, .iota.-
 Neocarraoctaose 237069-79-3, .iota.-
 Neocarradecaose 237069-85-1, .iota.-
 Neocarradodecaose
 RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 (medicine for treating **apoptosis** dysfunction contg. **oligosaccharides**)

RE.CNT 3
 RE

- (1) Leland Stanford Junior University; WO 9502684 A 1995 HCAPLUS
- (2) Otsuka Pharmaceutical Co; EP 0552373 A 1993 HCAPLUS
- (3) Seikagaku Corp; EP 0795560 A 1997 HCAPLUS

L126 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2001 ACS
 AN 1998:774909 HCAPLUS
 DN 130:123794

TI CD36 is required for phagocytosis of **apoptotic** cells by human macrophages that use either a phosphatidylserine receptor or the vitronectin receptor (.alpha.v.beta.3)

AU Fadok, Valerie A.; Warner, Mary L.; Bratton, Donna L.; Henson, Peter M.
 CS Dep. Medicine, Pediatrics, National Jewish Medical Res. Center, Denver, CO, 80262, USA

SO J. Immunol. (1998), 161(11), 6250-6257

CODEN: JOIMA3; ISSN: 0022-1767

PB American Association of Immunologists

DT Journal

LA English

CC 15-10 (Immunochemistry)

AB In vivo, **apoptotic** cells are efficiently removed by professional or nonprofessional phagocytes, a process thought to be essential for tissue remodeling and resolu. of inflammation. Macrophages recognize **apoptotic** cells by several mechanisms, including recognition of exposed phosphatidylserine (PS); however, PS recognition on **apoptotic** cells has not been identified as a feature of human macrophages. The purpose of this study was to detd. whether human monocyte-derived macrophages could be stimulated to recognize PS, defined as inhibition of phagocytosis by PS-contg. liposomes. We also assessed the potential roles for scavenger receptors, CD14, and lectins. Uptake of **apoptotic** neutrophils into unstimulated macrophages was blocked about 50% by Arg-Gly-Asp-Ser and anti-.alpha.v, and up to 20% by oxidized low d. lipoprotein and N-acetylglucosamine, implying a major role for integrin and minor roles of scavenger and lectin receptors. Uptake into macrophages stimulated with .beta.-1,3-glucan was blocked 50% by PS liposomes and 40% b y oxidized low d. lipoprotein, suggesting that the macrophages had switched from using integrin to recognition of PS. MEM-18 and 61D3 (anti-CD14 mAbs) were poor inhibitors of **apoptotic** neutrophil uptake, but good inhibitors of **apoptotic** lymphocyte uptake. The switch to PS recognition was accompanied by down-regulation of .alpha.v.beta.3 expression and function. Anti-CD36 blocked uptake into unstimulated or stimulated macrophages, suggesting CD36 involvement not only with the .alpha.v.beta.3 integrin mechanism (as previously reported) but also with PS recognition. A max. of 70% inhibition was achieved by combining anti-CD36 with either anti-av or PS liposomes.

ST CD36 macrophage phagocytosis phosphatidylserine receptor; vitronectin receptor CD36 macrophage phagocytosis

IT Receptors

RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (phosphatidylserine; requirement of CD36 in phagocytosis of **apoptotic** cells by human macrophages that use either a phosphatidylserine receptor or vitronectin receptor (.alpha.v.beta.3) and the role of other receptors)

IT **Apoptosis**

Lymphocyte

Macrophage

Neutrophil

Phagocytosis

(requirement of CD36 in phagocytosis of **apoptotic** cells by human macrophages that use either a phosphatidylserine receptor or vitronectin receptor (.alpha.v.beta.3) and the role of other receptors)

IT CD36 (antigen)

RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)

(requirement of CD36 in phagocytosis of **apoptotic** cells by human macrophages that use either a phosphatidylserine receptor or vitronectin receptor (.alpha.v.beta.3) and the role of other receptors)

IT CD14 (antigen)

RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (requirement of CD36 in phagocytosis of **apoptotic** cells by human macrophages that use either a phosphatidylserine receptor or vitronectin receptor (.alpha.v.beta.3) and the role of other receptors)

IT Integrin .alpha.v.beta.3

RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (requirement of CD36 in phagocytosis of **apoptotic** cells by human macrophages that use either a phosphatidylserine receptor or vitronectin receptor (.alpha.v.beta.3) and the role of other receptors)

IT Lectins

RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (requirement of CD36 in phagocytosis of **apoptotic** cells by

human macrophages that use either a phosphatidylserine receptor or vitronectin receptor (.alpha.v.beta.3) and the role of other receptors)

IT Phosphatidylserines

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(requirement of CD36 in phagocytosis of **apoptotic** cells by human macrophages that use either a phosphatidylserine receptor or vitronectin receptor (.alpha.v.beta.3) and the role of other receptors)

IT Scavenger receptors

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(requirement of CD36 in phagocytosis of **apoptotic** cells by human macrophages that use either a phosphatidylserine receptor or vitronectin receptor (.alpha.v.beta.3) and the role of other receptors)

RE.CNT 49

RE

- (1) Acton, S; J Biol Chem 1994, V269, P21003 HCAPLUS
- (2) Akaike, H; Trans Biomed Eng 1974, AC-19, P716
- (3) Akbar, A; J Exp Med 1994, V180, P1943 HCAPLUS
- (4) Bratton, D; J Biol Chem 1997, V272, P26159 HCAPLUS
- (5) Connor, J; J Biol Chem 1994, V269, P2399 HCAPLUS
- (6) Devitt, A; Nature 1997, V392, P505
- (7) Duvall, E; Immunology 1985, V56, P351 MEDLINE
- (8) Elomaa, O; Cell 1995, V80, P603 HCAPLUS
- (9) Endemann, G; J Biol Chem 1993, V268, P11811 HCAPLUS
- (10) Fadok, V; J Clin Invest 1998, V101, P890 HCAPLUS
- (11) Fadok, V; J Immunol 1992, V148, P2207 HCAPLUS
- (12) Fadok, V; J Immunol 1992, V149, P4029 HCAPLUS
- (13) Fadok, V; J Immunol 1993, V151, P4274 HCAPLUS
- (14) Flora, P; Eur J Immunol 1994, V24, P2625 HCAPLUS
- (15) Fukasawa, M; Exp Cell Res 1996, V222, P246 HCAPLUS
- (16) Gibson, P; Am J Resp Crit Care Med 1997, V155, PA296
- (17) Hart, S; J Immunol 1997, V159, P919 HCAPLUS
- (18) Haslett, C; Am J Pathol 1985, V119, P101 HCAPLUS
- (19) Hebbel, P; Blood 1984, V64, P733
- (20) Holness, C; J Biol Chem 1993, V268, P9661 HCAPLUS
- (21) Krieger, M; Annu Rev Biochem 1994, V63, P601 MEDLINE
- (22) Laird, N; Biometrics 1982, V38, P963 MEDLINE
- (23) Murao, K; J Biol Chem 1997, V272, P17551 HCAPLUS
- (24) Newman, S; J Exp Med 1982, V156, P430 MEDLINE
- (25) Ottnad, E; Proc Natl Acad Sci USA 1995, V92, P1391 HCAPLUS
- (26) Pearson, A; Curr Opin Immunol 1996, V8, P20 HCAPLUS
- (27) Platt, N; Proc Natl Acad Sci USA 1996, V93, P12456 HCAPLUS
- (28) Pradhan, D; Mol Biol Cell 1997, V8, P767 HCAPLUS
- (29) Ramprasad, M; Proc Natl Acad Sci USA 1995, V92, P9580 HCAPLUS
- (30) Ramprasad, M; Proc Natl Acad Sci USA 1996, V92, P14833
- (31) Ren, Y; J Exp Med 1995, V181, P1857 HCAPLUS
- (32) Ren, Y; J Immunol 1995, V154, P2366 HCAPLUS
- (33) Rigotti, A; J Biol Chem 1995, V270, P16221 HCAPLUS
- (34) Rose, D; Doctoral dissertation. University of Colorado 1996
- (35) Rose, D; J Immunol 1995, V155, P5819 HCAPLUS
- (36) Ryeom, S; J Biol Chem 1996, V271, P20536 HCAPLUS
- (37) SAS Institute; SAS/Stat Software: Changes and Enhancements Through Release 1996
- (38) Sambrano, G; Proc Natl Acad Sci USA 1994, V91, P3265 HCAPLUS
- (39) Sambrano, G; Proc Natl Acad Sci USA 1995, V92, P1396 HCAPLUS
- (40) Savill, J; J Clin Invest 1989, V84, P1518 HCAPLUS
- (41) Savill, J; J Clin Invest 1989, V83, P865 MEDLINE
- (42) Savill, J; J Clin Invest 1992, V90, P1513 HCAPLUS
- (43) Savill, J; Nature 1990, V343, P170 HCAPLUS
- (44) Schwartz, R; J Clin Invest 1985, V75, P1965 MEDLINE
- (45) Sparrow, C; J Biol Chem 1989, V264, P2599 HCAPLUS
- (46) Stern, M; Am J Pathol 1996, V149, P911 HCAPLUS
- (47) Terpstra, V; Proc Natl Acad Sci USA 1997, V94, P8127 HCAPLUS
- (48) Ugolini, V; Proc Natl Acad Sci USA 1980, V77, P6764 HCAPLUS
- (49) Utsugi, T; Cancer Res 1991, V51, P3062 HCAPLUS

AN 1998:569434 HCAPLUS
 DN 129:270273
 TI Ligand binding to the (1.fwdarw.3)-.beta.-D-glucan receptor stimulates NF.kappa.B activation, but not **apoptosis** in U937 cells
 AU Battle, James; Ha, Tuanzhu; Li, Chaunfu; Della Beffa, Vittorio; Rice, Peter; Kalbfleisch, John; Browder, William; Williams, David
 CS Immunopharmacology Research Group, Department of Surgery, East Tennessee State University, Johnson City, TN, 37614-0575, USA
 SO Biochem. Biophys. Res. Commun. (1998), 249(2), 499-504
 CODEN: BBRCA9; ISSN: 0006-291X
 PB Academic Press
 DT Journal
 LA English
 CC 1-7 (Pharmacology)
 AB Recent data suggest that sepsis stimulates macrophage **apoptosis** (Ao) with subsequent induction of macrophage dysfunction. Nuclear factor-kappaB (NF.kappa.B) activation has been linked to Ao in either a pro- or antiapoptotic role. Glucans are biol. response modifiers which exert antiseptic activity. This investigation examd. the effect of (1.fwdarw.3)-.beta.-D-glucan receptor binding by a high affinity ligand on Ao and NF.kappa.B activation in U937 cells in the presence or absence of LPS. A high affinity glucan ligand (IC50 = 23 nM) activated NF.kappa.B, but did not induce Ao or significantly alter LPS induced U937 Ao. These data indicate that: (i) modulation of the macrophage (1.fwdarw.3)-.beta.-D-glucan receptor stimulates NF.kappa.B; (ii) does not induce Ao or significantly diminish LPS induced Ao and (iii) activation of the U937 FAS receptor does not alter the relative Ao responses in glucan and LPS treated cells. (c) 1998 Academic Press.
 ST glucan receptor ligand sepsis macrophage **apoptosis**
 IT **Apoptosis**
 Macrophage
 Sepsis
 (ligand binding to the (1.fwdarw.3)-.beta.-D-glucan receptor stimulates NF.kappa.B activation, but not **apoptosis** in U937 cells)
 IT NF-.kappa.B
 Receptors
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (ligand binding to the (1.fwdarw.3)-.beta.-D-glucan receptor stimulates NF.kappa.B activation, but not **apoptosis** in U937 cells)
 IT 39464-87-4, Scleroglucan
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (ligand binding to the (1.fwdarw.3)-.beta.-D-glucan receptor stimulates NF.kappa.B activation, but not **apoptosis** in U937 cells)
 IT **9051-97-2**, (1.fwdarw.3)-.beta.-D-Glucan
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ligand binding to the (1.fwdarw.3)-.beta.-D-glucan receptor stimulates NF.kappa.B activation, but not **apoptosis** in U937 cells)

L126 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2001 ACS

AN 1998:60983 HCAPLUS
 DN 128:188387
 TI Cytotoxic effect against HeLa cells of polysaccharides from the lichen Ramalina celastri
 AU Leao, A. M. A. Carneiro; Buchi, D. Freitas; Iacomini, M.; Gorin, P. A. J.; Oliveira, M. B. M.
 CS Department of Animal Morphology and Physiology, Federal Rural University of Pernambuco, Recife, Brazil
 SO J. Submicrosc. Cytol. Pathol. (1997), 29(4), 503-509
 CODEN: JSCPEE; ISSN: 1122-9497
 PB Editrice Compositori
 DT Journal

LA English
 CC 1-6 (Pharmacology)
 AB The most active polysaccharides which show antitumoral activity are (1.fwdarw.3)-.beta.-D-glucans, branched or not at O-6. Since these structures are sometimes poorly sol. in aq. media, .alpha.-D-glucans and their chem. derivs., which are more sol., were also studied. The present object is to observe morphol. alterations in HeLa cells caused by two different polysaccharides obtained from the lichen Ramalina celastri, which are (1.fwdarw.3), (1.fwdarw.4)-linked .alpha.-D-glucan and its sulfated deriv. The cells were incubated in Eagle's medium in the absence or presence of each polysaccharide and routinely processed and analyzed by light and electron microscopy. Even though the .alpha.-D-glucan altered the cellular vol., cytoplasmic densities, and mitosis, the resulting monolayer was similar to the control. TEM anal. showed cytoplasmic blebbing and the presence of an amorphous electron-dense material free in the cytoplasm and interior membranes. The enhanced injury caused by the sulfated deriv. was apparent, altering cell adhesion and causing cell aggregation. Nuclear modifications such as fragmentation and condensation of chromatin under the nuclear envelope, which showed to be convoluted, suggested the occurrence of **cell death** by **apoptosis**.

ST antitumor polysaccharide lichen Ramalina
 IT Antitumor agents
 Apoptosis
 Cytotoxic agents
 Ramalina celastri
 (cytotoxic effect against HeLa cells of polysaccharides from the lichen Ramalina celastri)

IT Polysaccharides, biological studies
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (cytotoxic effect against HeLa cells of polysaccharides from the lichen Ramalina celastri)

IT **9051-97-2DP**, (1.fwdarw.3)-.beta.-D-Glucan, derivs.
 RL: BAC (Biological activity or effector, except adverse); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
 (cytotoxic effect against HeLa cells of polysaccharides from the lichen Ramalina celastri)

L126 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2001 ACS
 AN 1996:394881 HCAPLUS
 DN 125:56189
 TI Macrophage cytotoxicity against murine Meth A sarcoma involves nitric oxide-mediated **apoptosis**
 AU Sveinbjornsson, Baldur; Olsen, Randi; Seternes, Ole M.; Seljelid, Rolf
 CS Inst. Med. Biol., Univ. Tromsø, Tromsø, N-9037, Norway
 SO Biochem. Biophys. Res. Commun. (1996), 223(3), 643-649
 CODEN: BBRCA9; ISSN: 0006-291X
 DT Journal
 LA English
 CC 15-10 (Immunochemistry)
 AB We have studied the cytotoxic effect of stimulated macrophages on Meth A tumor cells in vitro. When stimulated with interferon-.gamma. and sol. . **beta.-1,3-D-glucan**, macrophages exerted cytotoxicity towards syngeneic Meth A tumor cells. This cytotoxicity was assocd. with a high level of nitric oxide prodn. Both **cell death** and nitric oxide prodn. were significantly inhibited by the addn. of aminoguanidine, a specific inhibitor of inducible nitric oxide synthase (iNOS), to the culture medium. The cytotoxic effect was accompanied by internucleosomal cleavage of DNA as shown by electrophoresis and DNA fragmentation assay.

ST macrophage cytotoxicity sarcoma nitric oxide **apoptosis**
 IT Deoxyribonucleic acids
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (cleavage; macrophage cytotoxicity against murine Meth A sarcoma involves nitric oxide-mediated **apoptosis** and)

- IT **Apoptosis**
 Macrophage
 Sarcoma
 (macrophage cytotoxicity against murine Meth A sarcoma involves nitric oxide-mediated **apoptosis**)
- IT Interferons
 RL: BAC (Biological activity or effector, except adverse); BIOL
 (Biological study)
 (.gamma., macrophage cytotoxicity against murine Meth A sarcoma involves nitric oxide-mediated **apoptosis** and)
- IT 10102-43-9, Nitric oxide, biological studies
 RL: BAC (Biological activity or effector, except adverse); BIOL
 (Biological study)
 (macrophage cytotoxicity against murine Meth A sarcoma involves nitric oxide-mediated **apoptosis**)
- . IT **9051-97-2**
 RL: BAC (Biological activity or effector, except adverse); BIOL
 (Biological study)
 (macrophage cytotoxicity against murine Meth A sarcoma involves nitric oxide-mediated **apoptosis** and)
- L126 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2001 ACS
 AN 1995:742064 HCAPLUS
 DN 123:132275
 TI Modulation of the **antitumor** effect and tissue distribution of highly **branched** (1.fwdarw.3)-**.beta.-D-glucan**, **SSG**, by **carrageenan**
 AU Suda, Masahiro; Ohno, Naohito; Adachi, Yoshiyuki; Yadomae, Toshiro
 CS Laboratory of Immunopharmacology of Microbial Products, Tokyo University of Pharmacy and Life Science, Tokyo, 192-03, Japan
 SO Biol. Pharm. Bull. (1995), 18(5), 772-5
 CODEN: BPBLEO; ISSN: 0918-6158
 DT Journal
 LA English
 CC 1-6 (Pharmacology)
 AB The action of **carrageenan** (CAR), a representative blocking reagent for phagocytes, on the antitumor effect and tissue distribution of highly branched (1.fwdarw.3)-**.beta.-D-glucan**, **SSG**, was examd. CAR inhibited the antitumor effect of i.p. administered **SSG** only when applied before inoculation of the tumor, and had little effect when applied after tumor inoculation. A similar result was obsd. when **SSG** was administered intralesionally. In contrast, CAR had considerable effect on tissue distribution of i.p. **SSG**. The differences with respect to the results in normal mice were: (1) the distribution of **SSG** from the peritoneal cavity to the rest of the body was inhibited, (2) large nos. of peritoneal exudate cells (PEC) were produced and a relatively high concn. of 3H-**SSG** was found in the PEC fraction 48 h after administration of 3H-**SSG**, (3) one week after administration, 3H-**SSG** was distributed to throughout the body but the amt. of 3H-**SSG** distributed was lower than in normal mice, (4) a significant amt. of 3H-**SSG** was recovered from ligaments (contg. omental milky spots, peritoneum, mesentery and assocd. fat) in which negligible amts. were found in normal mice. These results suggest that the inhibition of the antitumor effect of **SSG** by CAR probably results from the prevention of the natural resistance of mice which is related to phagocytic function, and that the distribution of **SSG** to throughout the body is significantly modulated by CAR.
- ST **SSG** antitumor activity tissue distribution **carrageenan**
 IT Animal tissue
 Neoplasm inhibitors
 (**carrageenan** modulation of antitumor effect and tissue distribution of **SSG**)
- IT Neoplasm inhibitors
 (sarcoma, **carrageenan** modulation of antitumor effect and tissue distribution of **SSG**)
- IT **9000-07-1, Carrageenan**
 RL: BAC (Biological activity or effector, except adverse); BIOL

(Biological study)

(**carrageenan** modulation of antitumor effect and tissue distribution of SSG)

IT 9051-97-2, SSG

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)

(**carrageenan** modulation of antitumor effect and tissue distribution of SSG)

L126 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2001 ACS

AN 1988:209 HCAPLUS

DN 108:209

*TI Antitumor activity of a highly branched (1.fwdarw.

3)-.beta.-D-glucan, SSG, obtained from

Sclerotinia sclerotiorum IFO 9395

. AU Ohno, Naohito; Kurachi, Kazuya; Yadomae, Toshiro

CS Tokyo Coll. Pharm., Hachioji, 192-03, Japan

SO J. Pharmacobio-Dyn. (1987), 10(9), 478-86

CODEN: JOPHDQ; ISSN: 0386-846X

DT Journal

LA English

CC 1-3 (Pharmacology)

Section cross-reference(s): 33

AB The antitumor activity of a highly branched (1.fwdarw.3)-.beta.

.-D-glucan, SSG, purified from the liq. culture filtrate of S.

sclerotiorum IFO 9395 and its several derivs. were tested in ICR mice bearing Sarcoma 180 cells. SSG was effective by both systemic (i.p. and

i.v.) and local (intratumoral) administrations on the solid form of

Sarcoma 180 in ICR mice and the mice acquired resistance to subsequent

inoculation of Sarcoma 180. However, SSG was not effective on the ascites

from Sarcoma 180. The pretreatment of ICR mice with **carrageenan**

suppressed the antitumor activity, suggesting the involvement of

macrophages on the antitumor activity. Derivs. prepd. from SSG by

periodate oxidn./borohydride redn. showed antitumor activity, but those

obtained after acetylation, carboxymethylation and hydroxyethylation were

less active. Apparently, SSG is a useful antitumor glucan which modifies

biol. responses and can be used as a source for some antitumor derivs.

ST Sclerotinia glucan antitumor

IT Macrophage

(in neoplasm inhibition by Sclerotinia sclerotiorum glucan derivs.)

IT Neoplasm inhibitors

(Sclerotinia sclerotiorum glucan derivs. as, prepn. of and structure in relation to)

IT Molecular structure-biological activity relationship

(neoplasm-inhibiting, of Sclerotinia sclerotiorum glucan derivs.)

IT 53238-80-5

RL: BAC (Biological activity or effector, except adverse); THU

(**Therapeutic use**); BIOL (Biological study); USES (Uses)

(neoplasm-inhibiting activity of, structure in relation to)

IT 53238-80-5DP, oxidized and reduced 111854-08-1P 111854-09-2P

111854-10-5P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (**Therapeutic use**); BIOL (Biological study);

PREP (Preparation); USES (Uses)

(prepn. and neoplasm-inhibiting activity of, structure in relation to)

L126 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2001 ACS

AN 1987:596356 HCAPLUS

DN 107:196356

TI Tumor cytotoxicity of polymorphonuclear leukocytes in beige mice: linkage of high responsiveness to linear .beta.-1,3

-D-glucan with the beige gene

AU Fukase, Shigeru; Inoue, Tomio; Arai, Shigeru; Sendo, Fujiro

CS Sch. Med., Yamagata Univ., Yamagata, 990-23, Japan

SO Cancer Res. (1987), 47(18), 4842-7

CODEN: CNREA8; ISSN: 0008-5472

DT Journal
 LA English
 CC 15-10 (Immunochemistry)
 Section cross-reference(s): 3
 AB Beige mice (bg/bg) have many functional defects in their leukocytes and these phenotypes are inherited in an autosomal recessive manner. The tumor cytotoxicity of polymorphonuclear leukocytes (PMN) obtained from bg/bg was studied. The intensity of tumor cytotoxicity of PMN induced by linear **.beta.-1,3-D-glucan** was higher in bg/bg PMN than in PMN of heterozygous control mice (bg/+). To analyze this phenomenon more precisely from the genetic viewpoint, the tumor cytotoxicity of PMN from mice obtained by several mating expts. was detd. The intensity of linear **.beta.-1,3-D-glucan**-induced PMN cytotoxicity was genetically defined and linked completely with the beige gene. In litter mates obtained from cross mating, PMN from only bg/bg showed higher tumor cytotoxicity than those from bg/+ or mice that do not possess the beige gene (+/+). Tumor cytotoxicity induced by other stimulants (phorbol myristate acetate and cytokines) was not higher in bg/bg than bg/+ or +/+ PMN. Thus, the high responsiveness to linear **.beta.-1,3-D-glucan** in terms of tumor cytotoxicity of PMN was detd. by the locus that is linked to the beige gene and is expressed in an autosomal recessive manner.
 ST tumor cytotoxicity polymorphonuclear leukocyte beige mouse; gene linkage beige glucan response
 IT Neoplasm
 (cytolysis of, by glucan-responsive polymorphonuclear leukocyte, in beige mouse)
 IT **Cytolysis**
 (of neoplasm, by glucan-responsive polymorphonuclear leukocyte, in beige mouse)
 IT Mouse
 (tumor cytotoxicity of glucan-responsive polymorphonuclear leukocyte in beige, gene linkage in)
 IT Leukocyte
 (polymorphonuclear, glucan responsiveness and tumor cytotoxicity of, in beige mouse, gene linkage in)
 IT Gene and Genetic element, animal
 RL: BIOL (Biological study)
 (bg, linkage of gene for glucan-responsive polymorphonuclear leukocyte and, of beige mouse)
 IT 9051-97-2
 RL: BIOL (Biological study)
 (linear, polymorphonuclear leukocyte responsiveness to, gene linkage in beige mouse with)

L126 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2001 ACS

AN 1987:405547 HCAPLUS

DN 107:5547

TI Macrophage stimulation with some structurally related polysaccharides

AU Artursson, Per; Edman, P.; Ericsson, J. L. E.

CS Biomed. Cent., Univ. Uppsala, Uppsala, S-75125, Swed.

SO Scand. J. Immunol. (1987), 25(3), 245-54

CODEN: SJIMAX; ISSN: 0300-9475

DT Journal

LA English

CC 15-10 (Immunochemistry)

Section cross-reference(s): 63

AB The macrophage-stimulating properties of some structurally related polysaccharides were studied in vitro. When the polysaccharides were presented to the macrophages in a sterically fixed form, i.e. as microparticles, they induced the release of interleukin 1 (IL-1) from the macrophages. Microparticulate **1,3-.beta.-glucan** (curdlan) nonspecific macrophage mediated tumor cell killing while **1,4-.alpha.-glucan** (starch), **1,6-.alpha.-glucan** (dextran), and **1,6-.alpha.-mannan** were without effect. The corresponding sol.

polysaccharides did not stimulate the macrophages. Kinetic studies showed that although IL-1 was released immediately after stimulation, the macrophages needed a time lag of several days to develop tumor cytotoxicity. The development of cytotoxicity paralleled binding of tumor cells to the macrophages. Resident and inflammatory peritoneal macrophages showed differences in their responses to the polysaccharides. Stationary, resident peritoneal macrophages stimulated by macroparticles secreted high levels of IL-1 but expressed a low cytotoxic activity, while newly recruited inflammatory macrophages released lower levels of IL-1 but readily killed the tumor cells. The influence of cyclooxygenase products on the IL-1 release and macrophage cytotoxicity was also investigated. When cyclooxygenase was blocked with indomethacin, a significantly higher release of IL-1, and then an increased cytotoxicity, were obtained with

1.3-.beta.-glucan stimulated

macrophages. Thus, microparticulate polysaccharides may be useful for studies on the induction of macrophage differentiation and also for studies on nonspecific cellular immune responses in vitro and in vivo.

ST macrophage stimulation polysaccharide; microparticle polysaccharide
macrophage stimulation

IT **Cytolysis**

(by macrophage, polysaccharide microparticles stimulation of)

IT Macrophage

(**cytolytic** activity of, interleukin 1 release by,
polysaccharide microparticles stimulation of)

IT Polysaccharides, biological studies

RL: BIOL (Biological study)

(acryloyl, microparticles, macrophage stimulated by, **cytolytic**
activity of and interleukin 1 release by)

IT Lymphokines and Cytokines

RL: FORM (Formation, nonpreparative)

(interleukin 1, formation of, by macrophage, polysaccharide
microparticles stimulation of)

IT Pharmaceutical dosage forms

(microparticles, acryloylated polysaccharide, macrophage stimulated by,
cytolytic activity of and interleukin 1 release by)

IT 39316-65-9 63653-15-6 108598-47-6 108598-84-1

RL: BIOL (Biological study)

(microparticles, macrophage stimulated by, **cytolytic**
activity of and interleukin 1 release by)

L126 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2001 ACS

AN 1985:202431 HCAPLUS

DN 102:202431

TI A soluble **.beta.-1,3-D-glucan**

derivative potentiates the cytostatic and **cytolytic** capacity of
mouse peritoneal macrophages in vitro

AU Seljelid, Rolf; Boegwald, Jarl; Hoffman, James; Larm, Olle

CS Inst. Med. Biol., Univ. Tromso, Tromso, N-9001, Norway

SO Immunopharmacology (1984), 7(1), 69-73

CODEN: IMMUDP; ISSN: 0162-3109

DT Journal

LA English

CC 15-10 (Immunochemistry)

AB An aminated **.beta.-1,3-D-glucan**

deriv., curdlan, is reported to render macrophages cytostatic to L-929
cells and to potentiate macrophage cytotoxicity to the tumor cells in
vitro.

ST curdlan glucan deriv tumor **cytolysis** macrophage

IT Neoplasm inhibitors

(curdlan as, macrophage in relation to)

IT **Cytolysis**

(of neoplasm, by peritoneal macrophage, enhancement of, by activated
curdlan)

IT Macrophage

(tumor **cytolysis** and cytostasis by, potentiation of, by
activated curdlan)

IT 54724-00-4
 RL: BIOL (Biological study)
 (tumor inhibition by macrophage enhancement by)

L126 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2001 ACS
 AN 1984:400346 HCAPLUS
 DN 101:346
 TI Early cellular responses in the peritoneal cavity of mice to
antitumor immunomodulators
 AU Morikawa, Kaoru; Kikuchi, Yoshiaki; Abe, Shigeru; Yamazaki, Masatoshi;
 Mizuno, Denichi
 CS Fac. Pharm. Sci., Teikyo Univ., Kanagawa, 199-01, Japan
 SO Gann (1984), 75(4), 370-8
 CODEN: GANNA2; ISSN: 0016-450X
 DT Journal
 LA English
 CC 1-6 (Pharmacology)
 AB The early cellular responses to antitumor immunomodulators and
 conventional inducers, esp. the polymorphonuclear leukocyte (PMN)
 responses, were examd. in the peritoneal cavity of mice to investigate
 their effect on primary defense mechanisms. Immunomodulators were
 classified into 5 groups in terms of PMN response on the basis of its
 duration (declining or persistent) and extent (high or low induction): 1)
 TAK (**.beta.-1,3-glucan**)-type
 (high, persistent), 2) lentinan-type (high, declining), 3) yeast
 mannan-type (low, declining), 4) LPS (lipopolysaccharide)-type (low,
 persistent), 5) others (no effect). Since the general PMN response is of
 the declining type, the persistence of PMN with TAK- and LPS-type
 immunomodulators is a characteristic of the PMN-inducing activity. TAK-
 and lentinan-type immunomodulators induced larger nos. of PMN and
 macrophages than conventional inducers. Thus, some types of
 immunomodulators have effects on the early host-defense mechanism.

ST peritoneal cavity cell antitumor immunomodulator; leukocyte
 polymorphonuclear antitumor immunomodulator

IT Macrophage
 (antitumor immunomodulators and conventional inducers effect on,
 antitumor mechanism in relation to)

IT Neoplasm inhibitors
 (immunomodulators, cellular response in peritoneal cavity to)

IT Caseins, biological studies
 Lipopolysaccharides
 Polysaccharides, biological studies
 RL: BIOL (Biological study)
 (macrophage and polymorphonuclear leukocyte in peritoneal cavity
 response to)

IT Immunity
 (modulators of, antitumor mechanism of)

IT Leukocyte
 (polymorphonuclear, antitumor immunomodulators and conventional
 inducers effect on, antitumor mechanism in relation to)

IT 68-11-1, biological studies 9000-07-1 9004-54-0, biological
 studies 9005-79-2, biological studies 9036-88-8 9051-97-2
 11028-71-0 14769-73-4 24939-03-5 37339-90-5 39325-01-4
 53678-77-6 61163-25-5
 RL: BIOL (Biological study)
 (macrophage and polymorphonuclear leukocyte in peritoneal cavity
 response to)

L126 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2001 ACS
 AN 1982:607775 HCAPLUS
 DN 97:207775
 TI Polysaccharides in **fungi**. Part XI. Antiinflammatory activity
 and **conformational** behavior of a **branched** (1 .fwdarw.
 3)-**.beta.-D-glucan** from an alkaline extract of
 Dictyophora indusiata Fisch
 AU Hara, Chihiro; Kiho, Tadashi; Tanaka, Yushiro; Ukai, Shigeo

- CS Gifu Coll. Pharm., Gifu, 502, Japan
 SO Carbohydr. Res. (1982), 110(1), 77-87
 CODEN: CRBRAT; ISSN: 0008-6215
 DT Journal
 LA English
 CC 1-3 (Pharmacology)
 AB T-5-N [53238-80-5], A (1.fwdarw.6)-branched (1.fwdarw.3)-**.beta**
.-D-glucan isolated from a M NaOH ext. of the fruit bodies of *D.*
indusiata markedly exhibited antiinflammatory effects on both
carrageenan-induced edema and scalded edematous hyperalgesia in
 rat hindpaws. The activities of T-5-N (25 mg/kg i.p. .times. 2) were more
 potent than those of phenylbutazone (25-50 mg/kg i.p. .times. 2). The
 conformational behavior of T-5-N was studied. Its mol. wt. in neutral
 soln. was about three times that in 0.25M NaOH. This finding, in addn. to
 the results of optical rotatory measurement and complex-formation with
 Congo Red, indicated that T-5-N has an ordered, triple-helical structure
 in neutral or slightly alk. soln. (<0.15M NaOH), and has single chains in
 highly alk. soln. (>0.25M NaOH). The conformational transition occurs at
 concns. of NaOH in the range of 0.15-0.25 M.
- ST T5N conformation antiinflammatory; structure activity T5N; glucan
 conformation antiinflammatory
 IT Inflammation inhibitors and Antiarthritics
 (glucans as, structure in relation to)
 IT Conformation and Conformers
 (of glucan)
 IT Molecular structure-biological activity relationship
 (inflammation-inhibiting, of glucans)
 IT 53238-80-5
 RL: BIOL (Biological study)
 (conformation and inflammation-inhibiting activity of)
 IT 9051-97-2D, (1.fwdarw.6)-branched derivs.
 RL: BIOL (Biological study)
 (inflammation-inhibiting activity of, structure in relation to)
- L126 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2001 ACS
 AN 1982:193044 HCAPLUS
 DN 96:193044
 TI Host-mediated **antitumor** polysaccharides. III. Fractionation,
 chemical structure, and **antitumor** activity of water-soluble
 homoglucons isolated from *kofukisarusukoshikake*, the fruit body of
Ganoderma applanatum
- AU Mizuno, Takashi; Hayashi, Katsuyuki; Arakawa, Masao; Shinkai, Kenkichi;
 Shimizu, Masako; Tanaka, Motohiro
 CS Fac. Agric., Shizuoka Univ., Shizuoka, Japan
 SO Shizuoka Daigaku Nogakubu Kenkyu Hokoku (1981), (31), 49-64
 CODEN: SDNKAA; ISSN: 0559-8850
 DT Journal
 LA Japanese
 CC 1-6 (Pharmacology)
 AB The polysaccharides in the fruit body of *G. applanatum* were composed of
 hemicelluloses 33.1%, cellulose 14.4%, pectic substances 1.5%, 50%
 EtOH-sol. polysaccharides 0.9%, and H2O-sol. polysaccharides 0.8%.
 D-Glucose, D-galactose, D-mannose, L-fucose, L-arabinose, D-xylose, and
 D-galacturonic acid were detected as the component sugars. Antitumor
 active **.beta.-D-glucans**, inactive **.beta.-D-**
glucan, **.alpha.-D-glucans** and heterogalactans were
 obtained by fractionation of the polysaccharides. By various chromatog.
 methods, gel chromatog., electrophoresis, and ultracentrifugation, 3
.beta.-D-glucans were obtained. Chem. analyses and 1H-
 and 13C-NMR showed that the 3 **.beta.-D-glucans** were
 composed of a linear **.beta.-(1.fwdarw.3)-linked D-glucopyranosyl**
 backbone having a single **.beta.-(1.fwdarw.6)-glucopyranoside**
 branch for every 3-5 **.beta.-(1.fwdarw.3)-glucopyranoside** linear
 linkages, with mol. wts. of 1.05 .times. 10⁶, 3.12 .times. 10⁵, and 2.43
 .times. 10³, resp. The first two **.beta.-D-glucans**
 markedly inhibited the growth of Sarcoma 180 in mice given at 1-5 mg/kg.

The third **.beta.-D-glucan** did not show any antitumor activity.

ST antitumor polysaccharide Ganoderma fruit body; heterogalactan antitumor Ganoderma fruit body; glucan antitumor Ganoderma fruit body

IT Polysaccharides, biological studies

RL: BIOL (Biological study)

(isolation from Ganoderma applanitum and neoplasm inhibiting activity and structure of)

IT Molecular structure, natural product

(of glucans of Ganoderma applanitum)

IT Ganoderma applanatum

(polysaccharides isolation from, neoplasm inhibiting activity and structure of)

IT Neoplasm inhibitors

(polysaccharides of Ganoderma applanitum)

IT **9041-22-9**

RL: BIOL (Biological study)

(isolation from Ganoderma applanitum and neoplasm inhibiting activity and structure of)

IT **9037-55-2D**, hetero- 9074-78-6 53238-80-5

RL: BIOL (Biological study)

(isolation from Ganoderma applanitum and neoplasm inhibiting activity of)

L126 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2001 ACS

AN 1981:404930 HCAPLUS

DN 95:4930

TI **Conformational** analysis of antigenic polysaccharides (**.alpha.1** .fwdarw. 6)-D-**glucan** and (**.beta.1** .fwdarw. 6)-D-galactan

AU Lipkind, G. M.; Kochetkov, N. K.

CS N. D. Zelinskii Inst. Org. Chem., Moscow, USSR

SO Bioorg. Khim. (1981), 7(5), 721-8

CODEN: BIKHD7

DT Journal

LA Russian

CC **15-2** (Immunochemistry)

Section cross-reference(s): 33

AB Theor. conformation anal. was carried out for (**.alpha.1**.fwdarw.6)-D-**glucan** and (**.beta.1**.fwdarw.6)-D-galactan. The optimal structures of the polymers and the conformations which allow these antigenic polysaccharides to interact with antibodies were detd.

ST glucan galactan conformation antigenicity

IT Chains, chemical

(conformation of, of galactan and glucan antigens, antibody interaction in relation to)

IT Antigens

RL: BIOL (Biological study)

(determinants, of galactan and glucan, conformation in relation to)

IT Antibodies

RL: BIOL (Biological study)

(galactan and glucan structure in relation to interaction with)

IT 9012-72-0 **9037-55-2**

RL: PRP (Properties)

(structure and conformation of, interaction with antibodies in relation to)

L126 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2001 ACS

AN 1981:58110 HCAPLUS

DN 94:58110

TI Antimacrophage agents decrease the **antitumor** effect of a water-soluble carboxymethylated (1 .fwdarw. 3)-**.beta.-D-glucan**

AU Sasaki, Takuma; Tanaka, Motohiro

CS Res. Inst., Natl. Cancer Cent., Tokyo, 104, Japan

SO Eur. J. Cancer (1980), 16(9), 1271-3

CODEN: EJCAAH; ISSN: 0014-2964

DT Journal

LA English

CC 1-5 (Pharmacodynamics)

AB Antimacrophage agents such as silica and **carrageenan** significantly decreased the antitumor activity of noncytotoxic carboxymethylglucan (I) [61163-25-5] in mice with transplanted sarcoma 180 ascites tumor. Poly-2-vinylpyridine N-oxide, a macrophage stabilizing agent, reversed the effects of the antimacrophage agents on the activity of I. In vitro, I had no direct cytotoxic effects; macrophages obtained from tumor-bearing control mice also did not alter tumor cell proliferation. However, macrophages obtained 10 days after the last I administration caused a 60% inhibition of tumor cell proliferation. Thus, in vivo and in vitro studies with macrophages indicate that the antitumor activity of I is immunol. nonspecific and is mediated by macrophages.

ST macrophage polysaccharide antitumor

IT Macrophage

(neoplasm inhibiting activity of polysaccharide mediation by)

IT 61163-25-5

RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(neoplasm inhibiting activity of, macrophages mediation of)

=> fil reg

FILE 'REGISTRY' ENTERED AT 10:41:25 ON 13 JUN 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 11 JUN 2001 HIGHEST RN 340680-60-6

DICTIONARY FILE UPDATES: 11 JUN 2001 HIGHEST RN 340680-60-6

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

=> d ide can tot 1127

L127 ANSWER 1 OF 13 REGISTRY COPYRIGHT 2001 ACS

RN **237069-85-1** REGISTRY

CN .iota.-Neocarradodecaose (9CI) (CA INDEX NAME)

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXLIT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 131:161631

L127 ANSWER 2 OF 13 REGISTRY COPYRIGHT 2001 ACS

RN **237069-79-3** REGISTRY

CN .iota.-Neocarradodecaose (9CI) (CA INDEX NAME)

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXLIT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 131:161631

L127 ANSWER 3 OF 13 REGISTRY COPYRIGHT 2001 ACS
RN 237069-76-0 REGISTRY
CN .iota.-Neocarraoctaose (9CI) (CA INDEX NAME)
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 131:161631

L127 ANSWER 4 OF 13 REGISTRY COPYRIGHT 2001 ACS
RN 237069-74-8 REGISTRY
CN .iota.-Neocarrahexaose (9CI) (CA INDEX NAME)
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 131:161631

L127 ANSWER 5 OF 13 REGISTRY COPYRIGHT 2001 ACS
RN 237069-70-4 REGISTRY
CN .iota.-Neocarratetraose (9CI) (CA INDEX NAME)
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 131:161631

L127 ANSWER 6 OF 13 REGISTRY COPYRIGHT 2001 ACS
RN 39475-64-4 REGISTRY
CN D-Galactan, hydrogen sulfate (9CI) (CA INDEX NAME)
OTHER NAMES:
CN D-Galactan sulfate
CN DH 6322
CN Galactan sulfate
CN Polygalactose sulfate
DR 55787-14-9, 60001-17-4
MF H2 O4 S . x Unspecified
CI COM
PCT Manual registration
LC STN Files: ADISINSIGHT, AGRICOLA, BIOBUSINESS, BIOSIS, CA, CANCERLIT,
CAPLUS, DDFU, DRUGU, MEDLINE, NAPRALERT, PHAR, TOXLIT, USPATFULL

CM 1

CRN 9037-55-2
CMF Unspecified


CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 7664-93-9

CMF H2 O4 S



50 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

50 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:55843

REFERENCE 2: 133:317030

REFERENCE 3: 133:147274

REFERENCE 4: 133:140242

REFERENCE 5: 132:317720

REFERENCE 6: 132:105537

REFERENCE 7: 131:161631

REFERENCE 8: 129:227868

REFERENCE 9: 128:225848

REFERENCE 10: 126:28866

L127 ANSWER 7 OF 13 REGISTRY COPYRIGHT 2001 ACS

RN 11016-36-7 REGISTRY

CN Porphyrane (8CI, 9CI) (CA INDEX NAME)

MF Unspecified

CI COM, MAN

LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, MEDLINE,
TOXLIT, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

44 REFERENCES IN FILE CA (1967 TO DATE)

5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

44 REFERENCES IN FILE CAPLUS (1967 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:55843

REFERENCE 2: 134:27460

REFERENCE 3: 133:134377

REFERENCE 4: 133:105237

REFERENCE 5: 132:92497

REFERENCE 6: 132:63286

REFERENCE 7: 132:30858

REFERENCE 8: 131:324052

REFERENCE 9: 131:161631

REFERENCE 10: 130:60714

L127 ANSWER 8 OF 13 REGISTRY COPYRIGHT 2001 ACS

RN 9062-07-1 REGISTRY

CN .iota.-Carrageenan (9CI) (CA INDEX NAME)

OTHER NAMES:

CN .beta.-Carrageenan 2,4'-bis(hydrogen sulfate)

CN .iota.-Carrageenin

CN Aubysel X 52

CN Carrageenan CSI 1

CN CSI 1

CN Deltagel 552

CN Eucheuma spinosum gum

CN Gelcarin GP 3367

CN Gelcarin ME 389

CN Gelcarin ME 621

CN Gelcarin SI

CN Genuvisco JJ

CN Genuvisco X 0908

CN Hygel SI 230

CN Pellugel ID

CN SeaSpen PF

CN Soageena MV 201

CN Soageena MV 220

CN Soageena MV 320

CN Soageena MV 330

CN Viscarin ME 389

CN Viscarin SD 309

DR 9079-01-0

MF Unspecified

CI PMS, COM, MAN

PCT Manual registration

LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, CHEMCATS,
CHEMLIST, CIN, CSCHM, DDFU, DRUGU, IFICDB, IFIPAT, IFIUDB, IPA,
NAPRALERT, NIOSHTIC, PIRA, PROMT, TOXLINE, TOXLIT, USPATFULL

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

736 REFERENCES IN FILE CA (1967 TO DATE)

21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

738 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:344602

REFERENCE 2: 134:339857

REFERENCE 3: 134:271270

REFERENCE 4: 134:256725

REFERENCE 5: 134:227233

REFERENCE 6: 134:227226

REFERENCE 7: 134:227225

REFERENCE 8: 134:223285

REFERENCE 9: 134:192537

REFERENCE 10: 134:191956

L127 ANSWER 9 OF 13 REGISTRY COPYRIGHT 2001 ACS

RN 9051-97-2 REGISTRY

CN .beta.-D-Glucan, (1.fwdarw.3)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (1,3)-.beta.-Glucan

CN (1.fwdarw.3)-.beta.-D-Glucan

CN Adjuvax

CN Drieline

CN GL 32

CN Glucan F

CN Guardoran

CN Highcareen GS

CN ImmuStim

CN Poly(1.fwdarw.3)-.beta.-D-glucan

CN Polysaccharide 13140

CN SSG

CN TAK

CN TAK (polysaccharide)

CN TAK-N

CN Uniglucan 51

CN VitaStim

DR 9050-90-2, 9052-00-0, 130809-04-0, 31667-87-5, 199665-06-0

MF Unspecified

CI PMS, COM, MAN

PCT Manual registration

LC STN Files: ADISINSIGHT, AGRICOLA, AIDSLINE, ANABSTR, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CIN, DDFU, DRUGNL, DRUGU,
DRUGUPDATES, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, NIOSHTIC,
PHAR, PROMT, RTECS*, TOXLINE, TOXLIT, USPATFULL

(*File contains numerically searchable property data)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

1014 REFERENCES IN FILE CA (1967 TO DATE)

119 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1015 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:349966

REFERENCE 2: 134:349702

REFERENCE 3: 134:348038

REFERENCE 4: 134:338155

REFERENCE 5: 134:330776

REFERENCE 6: 134:330763

REFERENCE 7: 134:261872

REFERENCE 8: 134:256583

REFERENCE 9: 134:251313

REFERENCE 10: 134:234206

L127 ANSWER 10 OF 13 REGISTRY COPYRIGHT 2001 ACS

RN 9041-22-9 REGISTRY

CN .beta.-D-Glucan (9CI) (CA INDEX NAME)

OTHER NAMES:

CN .beta.-Glucan

CN .beta.-Glucosylglucan

CN Biopoly P 3
CN Epiglucan
CN Fibosel
MF Unspecified
CI PMS, COM, MAN
PCT Manual registration
LC STN Files: AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, CA, CABA, CAPLUS,
CBNB, CEN, CHEMCATS, CIN, CSCHEM, IFICDB, IFIPAT, IFIUDB, IPA, NIOSHTIC,
PIRA, PROMT, TOXLINE, TOXLIT, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

1383 REFERENCES IN FILE CA (1967 TO DATE)

54 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1387 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:352534
REFERENCE 2: 134:339847
REFERENCE 3: 134:316161
REFERENCE 4: 134:310037
REFERENCE 5: 134:307135
REFERENCE 6: 134:285018
REFERENCE 7: 134:280084
REFERENCE 8: 134:265585
REFERENCE 9: 134:265579
REFERENCE 10: 134:265281

L127 ANSWER 11 OF 13 REGISTRY COPYRIGHT 2001 ACS

RN 9037-55-2 REGISTRY

CN D-Galactan (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Galactan

AR 39300-87-3

DR 9046-30-4, 9065-98-9

MF Unspecified

CI PMS, COM, MAN

PCT Manual registration

LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CEN,
CHEMLIST, CIN, EMBASE, IFICDB, IFIPAT, IFIUDB, NAPRALERT, PIRA, PROMT,
TOXLIT, USPATFULL

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

473 REFERENCES IN FILE CA (1967 TO DATE)

65 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

475 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:349830
REFERENCE 2: 134:339847
REFERENCE 3: 134:251264
REFERENCE 4: 134:204806
REFERENCE 5: 134:192256

REFERENCE 6: 134:190425

REFERENCE 7: 134:177523

REFERENCE 8: 134:163832

REFERENCE 9: 134:159963

REFERENCE 10: 134:97632

L127 ANSWER 12 OF 13 REGISTRY COPYRIGHT 2001 ACS

RN 9002-18-0 REGISTRY

CN Agar (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Agar-agar (8CI)

OTHER NAMES:

CN Agar Agar Flake

CN Agargel

CN Agaropectin, mixt. with agarose

CN Agarose, mixt. with agaropectin

CN Bacto-agar

CN Bengal gelatin

CN Bengal isinglass

CN Ceylon isinglass

CN Chinese isinglass

CN D 100

CN D 100 (polysaccharide)

CN Deltagar LTS

CN Difco Bacto agar

CN Digenea simplex mucilage

CN GAM medium

CN Gelose

CN Japan agar

CN Japan isinglass

CN Kantenmatsu

CN Laylor Carang

CN Luxara 1253

CN Oxoid III

CN Oxoid L 11

CN Phytagar

CN S 100

CN S 100 (polysaccharide)

CN UP 37

MF Unspecified

CI PMS, COM, MAN

PCT Manual registration, Polyother, Polyother only

LC STN Files: AGRICOLA, AIDSLINE, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USPATFULL

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

3642 REFERENCES IN FILE CA (1967 TO DATE)

76 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

3651 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:357388

REFERENCE 2: 134:356923

REFERENCE 3: 134:354770

REFERENCE 4: 134:354244
REFERENCE 5: 134:352588
REFERENCE 6: 134:350195
REFERENCE 7: 134:339847
REFERENCE 8: 134:338289
REFERENCE 9: 134:337939
REFERENCE 10: 134:337791

L127 ANSWER 13 OF 13 REGISTRY COPYRIGHT 2001 ACS

RN 9000-07-1 REGISTRY

CN Carrageenan (9CI) (CA INDEX NAME)

OTHER NAMES:

CN .kappa..lambda.-Carrageenan

CN Aubygum x 2

CN Aubygum X 23

CN Carrageenan GH

CN Carrageenan gum

CN Carrageenan SWG-J

CN Carrageenin

CN Carragheen

CN Carragheenan

CN EC 4000

CN FK 6101

CN FK 6120

CN Gelcarin GP 37ANF

CN Gelcarin HWG

CN Gelloid J

CN Gelozone

CN Genugel LC 4

CN Genugel LC 5

CN Genugel MG 11

CN Genugel RLV

CN Genuvisco J

CN Gum carrageenan

CN Gum chon 2

CN Gum chond

CN Inagel E 150

CN LSS 1

CN ME 913

CN Newgelin LB 4

CN Norsk gelatan

CN Pellugel

CN Pencogel

CN Satiagel NP 5B

CN Sea-Pi Gum FA

CN Seagel GH

CN Seagel Pet

CN SeaKem carrageenin

CN Sherex IC 109

CN Soa Ace WX 138

CN Soageena MM 501

CN Soageena MW 351

CN Soageena WX 560

CN Takaragen L

CN TIC Pretested Colloid 775

CN TK 1

CN TK 1 (polysaccharide)

CN Viscarin IC 3820

CN Viscarin SD 389

CN Viscarin TP 389

CN X 5189
DR 8040-42-4, 9000-13-9, 9000-27-5, 78005-48-8
MF Unspecified
CI PMS, COM, MAN
PCT Manual registration, Polyother, Polyother only
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, APILIT, APILIT2, APIPAT,
APIPAT2, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS,
CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DRUGU, EMBASE,
HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT,
NIOSHTIC, PIRA, PROMT, RTECS*, TOXLINE, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

3467 REFERENCES IN FILE CA (1967 TO DATE)

107 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

3475 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:357411
REFERENCE 2: 134:357388
REFERENCE 3: 134:357359
REFERENCE 4: 134:354003
REFERENCE 5: 134:352373
REFERENCE 6: 134:350284
REFERENCE 7: 134:344332
REFERENCE 8: 134:339857
REFERENCE 9: 134:339847
REFERENCE 10: 134:338705

=> fil medline

FILE 'MEDLINE' ENTERED AT 10:42:00 ON 13 JUN 2001

FILE LAST UPDATED: 11 JUN 2001 (20010611/UP). FILE COVERS 1958 TO DATE.

On April 22, 2001, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE now contains new records from the former NLM HEALTH STAR database. These records have an Entry Date and Update Date of 20010223.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2001 vocabulary. Enter HELP THESAURUS for details.

The OLDMEDLINE file segment now contains data from 1958 through 1965. Enter HELP CONTENT for details.

Left, right, and simultaneous left and right truncation are available in the Basic Index. See HELP SFIELDS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.

=> d all tot 1158

L158 ANSWER 1 OF 9 MEDLINE
AN 1999218620 MEDLINE

DN 99218620 PubMed ID: 10200509
 TI The role of phosphatidylserine in recognition of **apoptotic** cells by phagocytes.
 CM Comment in: Cell Death Differ. 1998 Jul;5(7):549-50
 AU Fadok V A; Bratton D L; Frasch S C; Warner M L; Henson P M
 CS Department of Pediatrics, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, Colorado 80206 USA.. fadokv@njc.org
 SO CELL DEATH AND DIFFERENTIATION, (1998 Jul) 5 (7) 551-62. Ref: 128
 Journal code: C7U; 9437445. ISSN: 1350-9047.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, ACADEMIC)
 LA English
 FS Priority Journals
 EM 199905
 ED Entered STN: 19990607
 Last Updated on STN: 20000303
 Entered Medline: 19990527
 AB Exposure of phosphatidylserine on the outer leaflet of the plasma membrane is a surface change common to many **apoptotic** cells. Normally restricted to the inner leaflet, phosphatidylserine appears as a result of decreased aminophospholipid translocase activity and activation of a calcium-dependent scramblase. Phosphatidylserine exposure has several potential biological consequences, one of which is recognition and removal of the **apoptotic** cell by phagocytes. It is still not clear which receptors mediate PS recognition on **apoptotic** cells; however, several interesting candidates have been proposed. These include the Class B scavenger and thrombospondin receptor CD36, an oxLDL receptor (CD68), CD14, annexins, beta2 glycoprotein I, gas-6 and a novel activity expressed on macrophages stimulated with digestible particles such as **beta-glucan**. Whether PS is the sole ligand recognized by phagocytes or whether it associated with other molecules to form a complex ligand remains to be determined.
 CT Check Tags: Animal; Human
 *Apoptosis
 *Phagocytes: PH, physiology
 *Phosphatidylserines: PH, physiology
 CN 0 (Phosphatidylserines)
 L158 ANSWER 2 OF 9 MEDLINE
 AN 1999081749 MEDLINE
 DN 99081749 PubMed ID: 9864222
 TI Modulation of endotoxin- and enterotoxin-induced cytokine release by in vivo treatment with beta-(1,6)-branched **beta**-(1,3)-**glucan**.
 AU Soltys J; Quinn M T
 CS Department of Veterinary Molecular Biology, Montana State University, Bozeman 59717, USA.
 NC S10 RR11877 (NCRR)
 SO INFECTION AND IMMUNITY, (1999 Jan) 67 (1) 244-52.
 Journal code: GO7; 0246127. ISSN: 0019-9567.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199901
 ED Entered STN: 19990209
 Last Updated on STN: 19990209
 Entered Medline: 19990128
 AB Leukocytes activated by endotoxin or enterotoxins release proinflammatory cytokines, thereby contributing to the cascade of events leading to septic shock. In the present studies, we analyzed the effects of in vivo administration of a soluble immunomodulator, beta-(1,6)-branched **beta**-(1,3)-**glucan** (soluble **beta**-**glucan**

), on toxin-stimulated cytokine production in monocytes and lymphocytes isolated from treated mice. In vitro stimulation of lymphocytes isolated from soluble **beta-glucan**-treated mice with lipopolysaccharide (LPS) resulted in enhanced production of interleukin-6 (IL-6) and suppressed production of tumor necrosis factor alpha (TNF-alpha), while stimulation of these cells with staphylococcal enterotoxin B (SEB) or toxic shock syndrome toxin 1 (TSST-1) resulted in enhanced production of gamma interferon (IFN-gamma) and suppressed production of IL-2 and TNF-alpha compared to that in cells isolated from untreated mice. In vitro stimulation of monocytes isolated from soluble **beta-glucan**-treated mice with LPS also resulted in suppressed TNF-alpha production, while stimulation of these cells with SEB or TSST-1 resulted in suppressed IL-6 and TNF-alpha production compared to that in cells isolated from untreated mice. Thus, the overall cytokine pattern of leukocytes from soluble **beta-glucan**-treated mice reflects suppressed production of proinflammatory cytokines, especially TNF-alpha. Taken together, our results suggest that treatment with soluble **beta-glucan** can modulate the induction of cytokines during sepsis, resulting in an overall decrease in host mortality.

CT Check Tags: Animal; Female; Support, Non-U.S. Gov't; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.

Adjuvants, Immunologic: AD, administration & dosage

Apoptosis: DE, drug effects

Apoptosis: IM, immunology

*Cytokines: ME, metabolism

*Enterotoxins: PD, pharmacology

***Glucans: AD, administration & dosage**

Injections, Intramuscular

***Lipopolysaccharides: PD, pharmacology**

Lymphocytes: IM, immunology

Lymphocytes: ME, metabolism

Mice

Mice, Inbred BALB C

Monocytes: IM, immunology

Monocytes: ME, metabolism

Staphylococcus aureus: IM, immunology

Superantigens: PD, pharmacology

RN **37361-00-5 (beta-glucan (1-6)); 39424-53-8 (enterotoxin B, staphylococcal); 9051-97-2 (beta-1,3-glucan)**

CN 0 (Adjuvants, Immunologic); 0 (Cytokines); 0 (Enterotoxins); 0 (**Glucans**); 0 (Lipopolysaccharides); 0 (Superantigens); 0 (enterotoxin F, Staphylococcal)

L158 ANSWER 3 OF 9 MEDLINE

AN 1999049859 MEDLINE

DN 99049859 PubMed ID: 9834113

TI CD36 is required for phagocytosis of **apoptotic** cells by human macrophages that use either a phosphatidylserine receptor or the vitronectin receptor (alpha v beta 3).

AU Fadok V A; Warner M L; Bratton D L; Henson P M

CS Department of Pediatrics, National Jewish Medical and Research Center, Denver, CO 80206, USA.. fadokv@njc.org

NC R01GM48211 (NIGMS)

SO JOURNAL OF IMMUNOLOGY, (1998 Dec 1) 161 (11) 6250-7.

Journal code: IFB; 2985117R. ISSN: 0022-1767.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 199812

ED Entered STN: 19990115

Last Updated on STN: 19990115

Entered Medline: 19981221

AB In vivo, **apoptotic** cells are efficiently removed by professional or nonprofessional phagocytes, a process thought to be essential for

tissue remodeling and resolution of inflammation. Macrophages recognize **apoptotic** cells by several mechanisms, including recognition of exposed phosphatidylserine (PS); however, PS recognition on **apoptotic** cells has not been identified as a feature of human macrophages. The purpose of this study was to determine whether human monocyte-derived macrophages could be stimulated to recognize PS, defined as inhibition of phagocytosis by PS-containing liposomes. We also assessed the potential roles for scavenger receptors, CD14, and lectins. Uptake of **apoptotic** neutrophils into unstimulated macrophages was blocked about 50% by Arg-Gly-Asp-Ser and anti-alpha(v), and up to 20% by oxidized low density lipoprotein and N-acetylglucosamine, implying a major role for integrin and minor roles for scavenger and lectin receptors. Uptake into macrophages stimulated with **beta-1,3-glucan** was blocked 50% by PS liposomes and 40% by oxidized low density lipoprotein, suggesting that the macrophages had switched from using integrin to recognition of PS. MEM-18 and 61D3 (anti-CD14 mAbs) were poor inhibitors of **apoptotic** neutrophil uptake, but good inhibitors of **apoptotic** lymphocyte uptake. The switch to PS recognition was accompanied by down-regulation of alpha(v)beta3 expression and function. Anti-CD36 blocked uptake into unstimulated or stimulated macrophages, suggesting CD36 involvement not only with the alpha(v)beta3 integrin mechanism (as previously reported) but also with PS recognition. A maximum of 70% inhibition was achieved by combining anti-CD36 with either anti-a(v) or PS liposomes.

CT Check Tags: Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
Adult

Antigens, CD14: PH, physiology

Antigens, CD36: ME, metabolism

*Antigens, CD36: PH, physiology

*Apoptosis: IM, immunology

Bacterial Proteins: ME, metabolism

Macrophages: IM, immunology

*Macrophages: ME, metabolism

*Phagocytosis: IM, immunology

*Phosphatidylserines: ME, metabolism

*Receptors, Cell Surface: PH, physiology

Receptors, Mitogen: PH, physiology

*Receptors, Vitronectin: PH, physiology

CN 0 (Antigens, CD14); 0 (Antigens, CD36); 0 (Bacterial Proteins); 0 (Phosphatidylserines); 0 (Receptors, Cell Surface); 0 (Receptors, Mitogen); 0 (Receptors, Vitronectin); 0 (msrA protein)

L158 ANSWER 4 OF 9 MEDLINE

AN 1998380290 MEDLINE

DN 98380290 PubMed ID: 9712725

TI Ligand binding to the (1 --> 3)-**beta-D-glucan** receptor stimulates NFkappaB activation, but not **apoptosis** in U937 cells.

AU Battle J; Ha T; Li C; Della Beffa V; Rice P; Kalbfleisch J; Browder W; Williams D

CS James H. Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee, 37614-0575, USA.

NC GM53522 (NIGMS)

SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1998 Aug 19) 249 (2) 499-504.

Journal code: 9Y8; 0372516. ISSN: 0006-291X.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199809

ED Entered STN: 19980925

Last Updated on STN: 19980925

Entered Medline: 19980911

AB Recent data suggest that sepsis stimulates macrophage **apoptosis** (Ao) with subsequent induction of macrophage dysfunction. Nuclear factor-kappaB (NFkappaB) activation has been linked to Ao in either a pro-

or antiapoptotic role. **Glucans** are biological response modifiers which exert antiseptis activity. This investigation examined the effect of (1-3)-**beta**-D-**glucan** receptor binding by a high affinity ligand on Ao and NFkappaB activation in U937 cells in the presence or absence of LPS. A high affinity **glucan** ligand (IC50 = 23 nM) activated NFkappaB, but did not induce Ao or significantly alter LPS induced U937 Ao. These data indicate that: i) modulation of the macrophage (1-3)-**beta**-D-**glucan** receptor stimulates NFkappaB; ii) does not induce Ao or significantly diminish LPS induced Ao and iii) activation of the U937 FAS receptor does not alter the relative Ao responses in **glucan** and LPS treated cells.

Copyright 1998 Academic Press.

CT Check Tags: Human; Support, U.S. Gov't, P.H.S.

Antibodies: ME, metabolism

Antibodies: PD, pharmacology

*Apoptosis

Cell Line

Escherichia coli

*Glucans: ME, metabolism

Ligands

Lipopolysaccharides: PD, pharmacology

*Macrophages: ME, metabolism

Membrane Glycoproteins: IM, immunology

Membrane Glycoproteins: ME, metabolism

*NF-kappa B: ME, metabolism

*Receptors, Immunologic: ME, metabolism

RN 39464-87-4 (scleroglucan); 9051-97-2 (beta-1,3-glucan)

CN 0 (Antibodies); 0 (FasL protein); 0 (Glucans); 0 (Ligands); 0 (Lipopolysaccharides); 0 (Membrane Glycoproteins); 0 (NF-kappa B); 0 (Receptors, Immunologic); 0 (beta-glucan receptor)

L158 ANSWER 5 OF 9 MEDLINE

AN 1998287220 MEDLINE

DN 98287220 PubMed ID: 9625538

TI Selective tumoricidal effect of soluble **proteoglucan** extracted from the basidiomycete, *Agaricus blazei* Murill, mediated via natural killer cell activation and **apoptosis**.

AU Fujimiya Y; Suzuki Y; Oshiman K; Kobori H; Moriguchi K; Nakashima H; Matumoto Y; Takahara S; Ebina T; Katakura R

CS Division of Immunology, Miyagi Cancer Center Research Institute, Natori, Japan.

SO CANCER IMMUNOLOGY, IMMUNOTHERAPY, (1998 May) 46 (3) 147-59.

Journal code: CN3; 8605732. ISSN: 0340-7004.

CY GERMANY: Germany, Federal Republic of

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199807

ED Entered STN: 19980716

Last Updated on STN: 19980716

Entered Medline: 19980709

AB We have isolated a novel type of natural tumoricidal product from the basidiomycete strain, *Agaricus blazei* Murill. Using the double-grafted tumor system in Balb/c mice, treatment of the primary tumor with an acid-treated fraction (ATF) obtained from the fruit bodies resulted in infiltration of the distant tumor by natural killer (NK) cells with marked tumoricidal activity. As shown by electrophoresis and DNA fragmentation assay, the ATF also directly inhibited tumor cell growth in vitro by inducing **apoptotic** processing; this **apoptotic** effect was also demonstrated by increased expression of the Apo2.7 antigen on the mitochondrial membranes of tumor cells, as shown by flow-cytometric analysis. The ATF had no effect on normal mouse splenic or interleukin-2-treated splenic mononuclear cells, indicating that it is selectively cytotoxic for the tumor cells. Cell-cycle analysis demonstrated that ATF-induced the loss of S phase in MethA tumor cells, but did not affect normal splenic mononuclear cells, which were mainly in

the G0G1 phase. Various chromatofocussing purification steps and NMR analysis showed the tumoricidal activity to be chiefly present in fractions containing (1-->4)-alpha-D-**glucan** and (1-->6)-**beta-D-glucan**, present in a ratio of approximately 1:2 in the ATF (molecular mass 170 kDa), while the final purified fraction, HM3-G (molecular mass 380 kDa), with the highest tumoricidal activity, consisted of more than 90% glucose, the main component being (1-->4)-alpha-D-**glucan** with (1-->6)-beta branching, in the ratio of approximately 4:1.

CT Check Tags: Animal; Male; Support, Non-U.S. Gov't

*Agaricus: CH, chemistry

*Agaricus: IM, immunology

Antigens, Surface: GE, genetics

*Apoptosis: IM, immunology

Carcinogens: PD, pharmacology

Cell Cycle: DE, drug effects

Chromatography

*Cytotoxicity, Immunologic: DE, drug effects

*Cytotoxicity, Immunologic: IM, immunology

DNA Fragmentation: DE, drug effects

Fungal Proteins: CH, chemistry

*Fungal Proteins: IM, immunology

*Fungal Proteins: PD, pharmacology

Immunophenotyping

*Killer Cells, Natural: IM, immunology

Leukocyte Count: DE, drug effects

Leukocytes, Mononuclear: CY, cytology

Leukocytes, Mononuclear: DE, drug effects

Leukocytes, Mononuclear: IM, immunology

Lymphocyte Transformation: PH, physiology

Magnetic Resonance Spectroscopy

Membrane Proteins: AN, analysis

Methylcholanthrene: PD, pharmacology

Mice

Mice, Inbred BALB C

Mitochondria: CH, chemistry

Neoplasm Transplantation

Neoplasms, Experimental: IM, immunology

Phenotype

Proteoglycans: CH, chemistry

*Proteoglycans: IM, immunology

*Proteoglycans: PD, pharmacology

Spleen: CY, cytology

Spleen: IM, immunology

Transplants

Tumor Cells, Cultured: CH, chemistry

Tumor Cells, Cultured: DE, drug effects

RN 56-49-5 (Methylcholanthrene)

CN 0 (Antigens, Surface); 0 (Carcinogens); 0 (Fungal Proteins); 0 (Membrane Proteins); 0 (Proteoglycans)

L158 ANSWER 6 OF 9 MEDLINE

AN 1998059976 MEDLINE

DN 98059976 PubMed ID: 9397587

TI Cytotoxic effect against HeLa cells of polysaccharides from the lichen Ramalina celastri.

AU Leao A M; Buchi D F; Iacomini M; Gorin P A; Oliveira M B

CS Department of Animal Morphology and Physiology, Federal Rural University of Pernambuco, Recife, PE, Brazil.

SO JOURNAL OF SUBMICROSCOPIC CYTOLOGY AND PATHOLOGY, (1997 Oct) 29 (4) 503-9.

Journal code: CMS; 8804312. ISSN: 1122-9497.

CY Italy

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199801
ED Entered STN: 19980129
Last Updated on STN: 20000303
Entered Medline: 19980114
AB The most active polysaccharides which show anti-tumoral activity are (1-->3)-**beta-D-glucans**, branched or not at O-6. Since these structures are sometimes poorly soluble in aqueous media, alpha-D-**glucans** and their chemical derivatives, which are more soluble, were also studied. The present object is to observe morphological alterations in HeLa cells caused by two different polysaccharides obtained from the lichen Ramalina celastri, which are (1-->3), (1-->4)-linked alpha-D-**glucan** and its sulphated derivative. The cells were incubated in Eagle's medium in the absence or presence of each polysaccharide and routinely processed and analysed by light and electron microscopy. Even though the alpha-D-**glucan** altered the cellular volume, cytoplasmic densities, and mitosis, the resulting monolayer was similar to the control. TEM analysis showed cytoplasmic blebbing and the presence of an amorphous electron-dense material free in the cytoplasm and interior membranes. The enhanced injury caused by the sulphated derivative was apparent, altering cell adhesion and causing cell aggregation. Nuclear modifications such as fragmentation and condensation of chromatin under the nuclear envelope, which showed to be convoluted, suggested the occurrence of cell death by **apoptosis**.
CT Check Tags: Human
*Hela Cells: DE, drug effects
*Hela Cells: PA, pathology
Hela Cells: UL, ultrastructure
*Lichens: ME, metabolism
Microscopy, Electron
*Polysaccharides: TO, toxicity
CN 0 (Polysaccharides)

L158 ANSWER 7 OF 9 MEDLINE
AN 96268732 MEDLINE
DN 96268732 PubMed ID: 8687449
TI Macrophage cytotoxicity against murine meth A sarcoma involves nitric oxide-mediated **apoptosis**.
AU Sveinbjornsson B; Olsen R; Seternes O M; Seljelid R
CS Institute of Medical Biology, University of Tromso, Norway.
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1996 Jun 25) 223 (3) 643-9.
Journal code: 9Y8; 0372516. ISSN: 0006-291X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199608
ED Entered STN: 19960828
Last Updated on STN: 19970203
Entered Medline: 19960816
AB We have studied the cytotoxic effect of stimulated macrophages on Meth A tumor cells in vitro. When stimulated with interferon-gamma and soluble **beta-1,3-D-glucan**, macrophages exerted cytotoxicity towards syngeneic Meth A tumor cells. This cytotoxicity was associated with a high level of nitric oxide production. Both cell death and nitric oxide production were significantly inhibited by the addition of aminoguanidine, a specific inhibitor of inducible nitric oxide synthase (iNOS), to the culture medium. The cytotoxic effect was accompanied by internucleosomal cleavage of DNA as shown by electrophoresis and DNA fragmentation assay.
CT Check Tags: Animal; Female
*Apoptosis
Cells, Cultured
Coculture
*Glucans: PD, pharmacology
Guanidines: PD, pharmacology

*Interferon Inducers: PD, pharmacology
 *Interferon-gamma, Recombinant: PD, pharmacology
 *Macrophage Activation
 Macrophage Activation: DE, drug effects
 Macrophages, Peritoneal: DE, drug effects
 *Macrophages, Peritoneal: IM, immunology
 Mice
 Mice, Inbred BALB C
 Mice, Inbred C57BL
 Microscopy, Electron
 Microscopy, Electron, Scanning
 *Nitric Oxide: PH, physiology
 Nitrites: ME, metabolism
 *Nitroprusside: PD, pharmacology
 *Sarcoma, Experimental: IM, immunology
 Sarcoma, Experimental: PA, pathology
 Sarcoma, Experimental: UL, ultrastructure
 Tumor Cells, Cultured

RN 10102-43-9 (Nitric Oxide); 15078-28-1 (Nitroprusside); 79-17-4
 (pimagedine); **9051-97-2 (beta-1,3-glucan)**

CN **0 (Glucans)**; 0 (Guanidines); 0 (Interferon Inducers); 0
 (Interferon-gamma, Recombinant); 0 (Nitrites)

L158 ANSWER 8 OF 9 MEDLINE

AN 96094479 MEDLINE

DN 96094479 PubMed ID: 7499871

TI Autocrine/paracrine involvement of platelet-activating factor and
 transforming growth factor-beta in the induction of phosphatidylserine
 recognition by murine macrophages.

AU Rose D M; Fadok V A; Riches D W; Clay K L; Henson P M

CS Department of Pediatrics, National Jewish Center for Immunology and
 Respiratory Medicine, Denver, CO 80206, USA.

NC AI09176 (NIAID)

GM48211 (NIGMS)

SO JOURNAL OF IMMUNOLOGY, (1995 Dec 15) 155 (12) 5819-25.

Journal code: IFB; 2985117R. ISSN: 0022-1767.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 199601

ED Entered STN: 19960217

Last Updated on STN: 19960217

Entered Medline: 19960118

AB The specific recognition of phosphatidylserine (PS) by macrophages is
 believed to be one means by which effete and **apoptotic** cells
 expressing PS on their outer membrane leaflet are targeted for
 phagocytosis. The aim of this study was to better understand the
 autocrine/paracrine factors involved in **beta-glucan**
 induction of PS recognition by macrophages. We provide evidence that both
 platelet-activating factor (PAF) and TGF-beta are involved in **beta**
-glucan induction of PS recognition. This is based on the
 observations that the PAF receptor antagonist WEB 2086 and Ab against
 TGF-beta each could partially inhibit **beta-glucan**
 -induced PS recognition when used alone and could completely inhibit
 induction when used in combination. PAF, like TGF-beta, was found to prime
 macrophages for PS recognition, which could then be triggered by
 costimulation with a nonspecific phagocytic stimulus, latex particles. We
 also provide evidence that the priming by PAF and that by TGF-beta can
 occur independently of each other. This is based on the observations that
 1) PAF priming was not blocked by anti-TGF-beta Ab, nor was TGF-beta
 priming prevented by WEB 2086; and 2) PAF did not increase the steady
 state level of TGF-beta mRNA, and TGF-beta did not induce PAF synthesis in
 these cells.

CT Check Tags: Animal; Support, U.S. Gov't, P.H.S.

Antibodies, Monoclonal: IM, immunology

Bone Marrow: CY, cytology
Cells, Cultured

Glucans: PD, pharmacology

Macrophage Activation: DE, drug effects

Macrophages: DE, drug effects

*Macrophages: ME, metabolism

Mice

Mice, Inbred C3H

*Phosphatidylserines: ME, metabolism

*Platelet Activating Factor: PH, physiology

Platelet Membrane Glycoproteins: AI, antagonists & inhibitors

Transforming Growth Factor beta: IM, immunology

*Transforming Growth Factor beta: PH, physiology

CN 0 (Antibodies, Monoclonal); 0 (**Glucans**); 0
(Phosphatidylserines); 0 (Platelet Activating Factor); 0 (Platelet
Membrane Glycoproteins); 0 (Transforming Growth Factor beta); 0 (platelet
activating factor receptor)

L158 ANSWER 9 OF 9 MEDLINE

AN 94014371 MEDLINE

DN 94014371 PubMed ID: 8409401

TI Particle digestibility is required for induction of the phosphatidylserine
recognition mechanism used by murine macrophages to phagocytose
apoptotic cells.

AU Fadok V A; Laszlo D J; Noble P W; Weinstein L; Riches D W; Henson P M

CS Department of Pediatrics, National Jewish Center for Immunology and
Respiratory Medicine, Denver, CO 80206.

NC CA50107 (NCI)

GM48211 (NIGMS)

HL27353 (NHLBI)

+

SO JOURNAL OF IMMUNOLOGY, (1993 Oct 15) 151 (8) 4274-85.

Journal code: IFB; 2985117R. ISSN: 0022-1767.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 199311,

ED Entered STN: 19940117

Last Updated on STN: 19940117

Entered Medline: 19931109

AB One of the characteristic features of programmed cell death in vivo is the
rapid recognition and removal of **apoptotic** cells by macrophages.

Although there are several potential mechanisms by which the macrophage

can identify a cell as **apoptotic**, it has been shown recently

that murine-elicited macrophages stereospecifically recognize

phosphatidylserine (PS) exposed on the surface of **apoptotic**

cells. The particulate stimulus, **beta-1, 3-glucan**,

stimulates bone marrow-derived macrophages to express several

characteristics of inflammatory macrophages, and induced these cells to

recognize PS on **apoptotic** cells; this activity was correlated

with the ability to form rosettes with PS-expressing RBC. Induction of PS

recognition in bone marrow-derived macrophages was associated with

digestibility of the stimulus, because L, but not D amino acid particles

or latex, were able to stimulate macrophage recognition of PS. The

requirement for digestibility could be bypassed by the addition of

exogenous TGF-beta, which induced macrophage recognition of PS after

stimulation with either latex or D amino acid particles. That endogenously

produced TGF-beta played a role in the **glucan**-stimulated

response was indicated by the ability of anti-TGF-beta antibodies to

inhibit digestible particle-induced recognition of PS. The induction of

the PS recognition mechanism correlated well with the expression of other

markers for the inflammatory phenotype. These studies indicate that the PS

receptor may be a marker for the inflammatory phenotype, which appears to

be induced by the phagocytosis of particulate digestible stimuli.

Endogenously produced TGF-beta is suggested to play an autocrine or

paracrine priming role in the induction of the PS receptor.
 CT Check Tags: Animal; Female; Male; Support, U.S. Gov't, P.H.S.
 ***Apoptosis**
 Cells, Cultured
 Diamide: PD, pharmacology
 Glucans: PD, pharmacology
 *Macrophages: PH, physiology
 Mice
 Mice, Inbred C3H
 Mice, Inbred C57BL
 Mice, Inbred DBA
 *Phagocytosis
 Phagocytosis: DE, drug effects
 *Phosphatidylserines: ME, metabolism
 Rosette Formation
 Transforming Growth Factor beta: PD, pharmacology
 RN 10465-78-8 (Diamide); 9051-97-2 (**beta-1,3-glucan**)
 CN 0 (**Glucans**); 0 (Phosphatidylserines); 0 (Transforming Growth
 Factor beta)

=> fil hcaplus
 FILE 'HCAPLUS' ENTERED AT 10:44:25 ON 13 JUN 2001
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 13 Jun 2001 VOL 134 ISS 25
 FILE LAST UPDATED: 12 Jun 2001 (20010612/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=> d all tot

L162 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2001 ACS
 AN 1996:456066 HCAPLUS
 DN 125:96228
 TI Keratan sulfate oligosaccharide fraction and drug containing the same
 IN Maruyama, Hiroshi; Morikawa, Kiyoshi; Tawada, Akira; Miyauchi, Satoshi;
 Yoshida, Keiichi; Asari, Akira
 PA Seikagaku Corporation, Japan
 SO PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 IC ICM C07H011-00
 ICS A61K031-70
 CC 63-7 (Pharmaceuticals)
 Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9616973	A1	19960606	WO 1995-JP2386	19951122
	W: AU, CA, CN, HU, JP, KR, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2206611	AA	19960606	CA 1995-2206611	19951122
	AU 9539356	A1	19960619	AU 1995-39356	19951122
	AU 704429	B2	19990422		
	EP 795560	A1	19970917	EP 1995-937170	19951122 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1174557	A	19980225	CN 1995-197492	19951122
	HU 77134	A2	19980302	HU 1997-1820	19951122
	US 5939403	A	19990817	US 1997-849925	19970602
	US 6159954	A	20001212	US 1999-317380	19990524
PRAI	JP 1994-298298	A	19941201		
	WO 1995-JP2386	W	19951122		

AB This invention relates to a keratan sulfate oligosaccharide comprising a di- to penta-saccharide which has a sulfated N-acetylglucosamine at the reducing end and wherein at least two hydroxyl groups per mol. have been sulfated, preferably one contg. a disaccharide of the formula Aal(6S)-GlcNAc(6S) (wherein Gal, GlcN, Ac and 6S represent, resp., galactose, glucosamine, acetyl and 6-O-sulfate) as the constituent; and antiphlogistic agent, antiallergic agent, immunoregulator, cell differentiation inducer and apoptosis inducer each contg. the above oligosaccharide and/or a pharmaceutically acceptable salt thereof as the active ingredient. As an example, an eye lotion was formulated contg. the keratan sulfate oligosaccharide Gal(6S).beta.1-4GlcNAc(6S).beta.1-3Gal(6S).beta.1-4GlcNAc(6S) [wherein Gal, GlcN, Ac and 6S are same as above] 10 and Na hyaluronate 2 mg/mL in pH 6.8-7.6 phosphate buffer. Keratan sulfate oligosaccharides were obtained by enzymic hydrolysis of keratan sulfate prep. from shark soft bone.

ST therapeutic keratan sulfate oligosaccharide

IT Inflammation inhibitors

(Keratan sulfate oligosaccharide fraction and drug contg. the same)

IT Allergy inhibitors

Immunomodulators

Oligosaccharides

RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(Keratan sulfate oligosaccharide fraction and drug contg. the same)

IT Animal cell

RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(differentiation inducer; Keratan sulfate oligosaccharide fraction and drug contg. the same)

IT Apoptosis

RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(inducer; Keratan sulfate oligosaccharide fraction and drug contg. the same)

IT Bone

RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(shark soft; therapeutic keratan sulfate oligosaccharide fraction from)

IT Shark

RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(soft bone; therapeutic keratan sulfate oligosaccharide fraction from)

IT Pharmaceutical dosage forms

(injections, Keratan sulfate oligosaccharide fraction and drug contg. the same)

IT Pharmaceutical dosage forms

(liposomes, Keratan sulfate oligosaccharide fraction and drug contg. the same)

IT Pharmaceutical dosage forms

(ointments, Keratan sulfate oligosaccharide fraction and drug contg. the same)

IT Pharmaceutical dosage forms
(solns., ophthalmic, Keratan sulfate oligosaccharide fraction and drug contg. the same)

IT 144095-99-8P 179074-66-9P 179074-67-0P
RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Keratan sulfate oligosaccharides contg.; Keratan sulfate oligosaccharide fraction and drug contg. the same)

IT 9056-36-4P, Keratan sulfate
RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oligosaccharide; Keratan sulfate oligosaccharide fraction and drug contg. the same)

L162 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2001 ACS

AN 1995:541403 HCAPLUS

DN 122:283855

TI Regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands

IN Crabtree, Gerald R.; Schreiber, Stuart L.; Spencer, David M.; Wandless, Thomas J.; Belshaw, Peter

PA Board of Trustees of the Leland Stanford Junior University, USA; President and Fellows of Harvard College

SO PCT Int. Appl., 134 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12N005-00

ICS C12N015-00; C07H015-12; C07K015-00; A61K031-70

CC 3-2 (Biochemical Genetics)

Section cross-reference(s): 1, 13, 64

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9502684	A1	19950126	WO 1994-US8008	19940718	<--
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	WO 9418317	A1	19940818	WO 1994-US1617	19940214	
	W: AT, AU, BB, BG, BR, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, SK					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	AU 9473363	A1	19950213	AU 1994-73363	19940718	
	AU 696991	B2	19980924			
	CN 1130401	A	19960904	CN 1994-193251	19940718	
	JP 09503645	T2	19970415	JP 1994-504752	19940718	
	EP 776359	A1	19970604	EP 1994-923515	19940718	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
	FI 9600165	A	19960126	FI 1996-165	19960115	
	US 6063625	A	20000516	US 1998-156855	19980916	
	US 6140120	A	20001031	US 1998-158010	19980916	
PRAI	US 1993-93499	A	19930716			
	US 1994-179143	A	19940107			
	WO 1994-US1617	A	19940214			
	US 1993-17931	A	19930212			
	US 1993-92977	A	19930716			
	US 1994-179748	A	19940107			
	US 1994-196043	B1	19940211			
	WO 1994-US8008	W	19940718			
AB	A general procedure is described for the regulated (inducible) dimerization or oligomerization of intracellular proteins and methods and					

materials are presented for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells. The procedure involves chimeric (or fused) proteins, DNA constructs encoding them, and ligand mols. capable of oligomerizing the chimeric proteins. The chimeric proteins contain at least one ligand-binding (or receptor) domain fused to an action domain capable of initiating apoptosis within a cell, and may also contain addnl. domains for (1) the regulatable or constitutive expression of desired genes and (2) intracellular targeting. The chimeric proteins are capable of binding to an FK506-type ligand, a cyclosporin A-type ligand, tetracycline, or a steroid ligand. One such chimeric protein is myristoylated CD3/FKBP12 (MZP3E) receptor consisting of (1) a c-src fragment sufficient for myristoylation, (2) the cytoplasmic tail of .zeta. (a component of the B cell receptor), (3) 3 consecutive domains of the FKBP12 immunophilin, and (4) a flu epitope tag; oligomerization/apoptosis is induced by a dimeric deriv. of FK506. Syntheses are reported for the prepn. of dimeric and "bumped" (contg. steric bulky groups) derivs. of FK506 and cyclosporin A. The overall procedures allows ligand-mediated oligomerization for regulated gene therapy.

- ST apoptosis programmed chimeric protein genetic engineering; FK506 binding chimeric protein apoptosis; cyclosporin binding chimeric protein apoptosis; FKBP12 chimeric protein programmed apoptosis; cyclophilin chimeric protein programmed apoptosis; Fas antigen chimeric protein programmed apoptosis
- IT Proteins, specific or class
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (apoptosis-inducing, fusion products with ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)
- IT Receptors
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (fusion products with apoptosis-inducing protein domains; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)
- IT Apoptosis
 (programmed; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)
- IT Genetic engineering
 Immunosuppressants
 Pharmaceuticals
 Transformation, genetic
 (regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)
- IT Virus, animal
 (vector; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)
- IT Antigen receptors
 Receptors
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (BCR (B-cell antigen receptors), .zeta. chain cytoplasmic tail, fusion products with ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)
- IT Antigens
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (CD3, fusion products with apoptosis-inducing protein domains and ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)
- IT Proteins, specific or class

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (FKBP-12 (FK 506-binding protein, 12,000-mol.-wt.), fusion products with apoptosis-inducing protein domains; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Antigens

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Fas, fusion products with ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Ribonucleic acid formation factors

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (HNF-1 (hepatocyte nuclear factor 1), fusion products with apoptosis-inducing protein domains and ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Histocompatibility antigens

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (MHC (major histocompatibility antigen complex), class II, I-E chain signal peptide, fusion products with apoptosis-inducing protein domains and ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Proteins, specific or class

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (NLS (nuclear location signal sequence)-contg., fusion products with apoptosis-inducing protein domains and ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Ribonucleic acid formation factors

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Vmw65 (virion-assocd. stimulatory protein, 65,000-mol.-wt.), fusion products with apoptosis-inducing protein domains and ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Virus, animal

(adeno-, vector; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Virus, animal

(adeno-assocd., vector; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Proteins, specific or class

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (cyclophilins, fusion products with apoptosis-inducing protein domains; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Proteins, specific or class

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (fusion products, regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Ribonucleic acid formation factors

RL: BAC (Biological activity or effector, except adverse); BPN

(Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (gene GAL4, fusion products with apoptosis-inducing protein domains and ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Proteins, specific or class
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (gene c-src, fusion products with apoptosis-inducing protein domains and ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Therapeutics
 (geno-, regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Proteins, specific or class
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (immunophilins, fusion products with apoptosis-inducing protein domains; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Lymphokine and cytokine receptors
 Receptors
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (interleukin 2, Tac chain, fusion products with apoptosis-inducing protein domains and ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Virus, animal
 (retro-, vector; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Peptides, biological studies
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (signal, fusion products with apoptosis-inducing protein domains and ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Lymphokine and cytokine receptors
 Receptors
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (tumor necrosis factor-.alpha., fusion products with ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT 161140-27-8P 161140-28-9P 161140-29-0P 161140-30-3P 161140-31-4P
 161140-32-5P 162926-19-4P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (FK506-type and cyclosporin-type ligands for regulated apoptosis by chimeric proteins)

IT 100-46-9, Benzylamine, reactions 124-09-4, 1,6-Hexanediamine, reactions 373-44-4, 1,8-Octanediamine 539-48-0, p-Xylylenediamine 646-25-3, Decamethylenediamine 4097-89-6 38721-52-7 51857-17-1 89270-28-0 133941-75-0 138957-22-9 138957-23-0 161140-22-3
 RL: RCT (Reactant)
 (FK506-type and cyclosporin-type ligands for regulated apoptosis by chimeric proteins)

IT 133523-46-3P 152406-15-0P 152406-19-4P 152406-20-7P 154074-71-2P
 155684-96-1P 161140-18-7P 161140-19-8P 161140-20-1P 161140-21-2P
 161140-23-4P 161140-24-5P 161247-38-7P 162926-14-9P 162926-15-0P
 162926-16-1P 162926-17-2P 162926-18-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(FK506-type and cyclosporin-type ligands for regulated apoptosis by
chimeric proteins)

IT 111710-64-6P 111722-74-8P 134166-82-8P 134166-84-0P 161140-25-6P
161140-26-7P 162926-20-7P 162926-21-8P 162926-22-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(FK506-type and cyclosporin-type ligands for regulated apoptosis by
chimeric proteins)

IT 60-54-8P, Tetracycline 53123-88-9P, Rapamycin 59865-13-3DP,
Cyclosporin A, derivs. 104987-11-3DP, FK506, derivs. 104987-12-4P,
FK520

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(regulated apoptosis by chimeric proteins binding to FK506-type and
cyclosporin-type ligands)

L162 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2001 ACS

AN 1995:377088 HCAPLUS

DN 122:153359

TI Regulated transcription of target genes with dimeric ligands which cause
chimeric receptor proteins to oligomerize and induce gene transcription

IN Crabtree, Gerald R.; Schreiber, Stuart L.; Spencer, David M.; Wandless,
Thomas J.; Belshaw, Peter

PA Leland Stanford Junior University, USA; Harvard College

SO PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12N015-00

ICS C12N005-00; C12N005-06; C12N015-11; C12P021-06; C12P021-00

CC 3-1 (Biochemical Genetics)

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9418317	A1	19940818	WO 1994-US1617	19940214
	W: AT, AU, BB, BG, BR, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP,				
	KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,				
	BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2155728	AA	19940818	CA 1994-2155728	19940214
	AU 9462403	A1	19940829	AU 1994-62403	19940214
	AU 690898	B2	19980507		
	CN 1119876	A	19960403	CN 1994-191558	19940214
	HU 73101	A2	19960628	HU 1995-2370	19940214
	EP 804561	A1	19971105	EP 1994-909629	19940214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	CA 2167282	AA	19950126	CA 1994-2167282	19940718
	WO 9502684	A1	19950126	WO 1994-US8008	19940718 <--
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU,				
	JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO,				
	RU, SD, SE, SK, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,				
	BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9473363	A1	19950213	AU 1994-73363	19940718
	AU 696991	B2	19980924		
	HU 73100	A2	19960628	HU 1996-83	19940718
	JP 09503645	T2	19970415	JP 1994-504752	19940718
	US 5871753	A	19990216	US 1995-473985	19950607
	FI 9503812	A	19950811	FI 1995-3812	19950811
	FI 9600165	A	19960126	FI 1996-165	19960115
	AU 9878807	A1	19981008	AU 1998-78807	19980806
	US 6063625	A	20000516	US 1998-156855	19980916
	US 6140120	A	20001031	US 1998-158010	19980916
PRAI	US 1993-17931	A	19930212		
	US 1993-92977	A	19930716		

US 1994-179748 A 19940107
 US 1993-93499 A 19930716
 US 1994-179143 A 19940107
 US 1994-196043 B1 19940211
 WO 1994-US1617 W 19940214
 WO 1994-US8008 W 19940718

- AB A general procedure for regulating (inducing) dimerization or oligomerization of chimeric proteins is presented. The chimeric proteins contain a receptor domain and another protein domain capable of initiating a biol. process. The chimeric proteins can be induced to assoc. by treating the cells or organisms that harbor them with cell-permeable, synthetic ligands. The dimers/oligomers bind to a transcription control element and stimulate transcription of the gene to which it is assocd. The syntheses of FK-506 dimers are presented. Such dimers were used to induce: (1) the intracellular aggregation of the cytoplasmic tail of the zeta chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene.
- ST gene transcription regulation ligand dimer; receptor protein chimeric oligomerization transcription
- IT Nucleic acids
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (antisense; regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)
- IT Ribonucleic acid formation factors
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (fusion protein with receptor; regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)
- IT Peptides, biological studies
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (intracellular targeting; regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)
- IT Animal cell
 (mammalian; regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)
- IT Animal
 Apoptosis
 Cell
 Insect
 Mammal
 Mouse
 Plant
 Rodent
 Transcription, genetic
 Worm
 (regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)
- IT Ribozymes
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)
- IT Ligands
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)

IT Receptors

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)

IT Steroids, reactions

RL: RCT (Reactant)

(regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)

IT Proteins, specific or class

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(surface membrane or secreted or cytoplasmic; regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)

IT Genetic element

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(transcription control element; regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)

IT Antigens

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(CD3, .zeta. subunit, fusion protein with receptor; regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)

IT Proteins, specific or class

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(DNA-binding, fusion protein with receptor; regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)

IT Antigens

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(Fas, fusion products with immunophilins; regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)

IT Virus, animal

(adeno-, vector; regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)

IT Virus, animal

(adeno-assocd., vector; regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)

IT Gene

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chimeric, regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)

IT Proteins, specific or class

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(cyclophilins, fusion products with Fas antigens; regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)

IT Ribonucleic acid formation factors

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(gene GAL4, fusion products with immunophilins; regulated transcription

- of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)
- IT Proteins, specific or class
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (immunophilins, fusion products with CD3; regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)
- IT Virus, animal
 (retro-, vector; regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)
- IT 161140-21-2P 161140-27-8P 161140-28-9P 161140-29-0P 161140-30-3P
 161140-31-4P 161140-32-5P
 RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of immunophilin dimers for regulation of transcription of target genes)
- IT 100-46-9, Benzylamine, reactions 539-48-0, p-Xylylenediamine
 74124-79-1, N,N'-Disuccinimidyl carbonate 133523-46-3 133941-75-0
 138957-23-0 161140-22-3
 RL: RCT (Reactant)
 (prepn. of immunophilin dimers for regulation of transcription of target genes)
- IT 152406-15-0P 152406-16-1P 152406-19-4P 152406-20-7P 154074-71-2P
 155684-96-1P 161140-18-7P 161140-19-8P 161140-20-1P 161140-23-4P
 161140-24-5P 161140-25-6P 161247-38-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of immunophilin dimers for regulation of transcription of target genes)
- IT 152406-17-2, FK 1012A 152406-18-3, FK 1012B 161140-26-7
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)
- IT 60-54-8, Tetracycline 53123-88-9, Rapamycin 59865-13-3, Cyclosporin A
 79217-60-0, Cyclosporin 104987-11-3, FK506 104987-12-4, FK520
 RL: RCT (Reactant)
 (regulated transcription of target genes with dimeric ligands which cause chimeric receptor proteins to oligomerize and induce gene transcription)

L162 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2001 ACS

AN 1993:161051 HCAPLUS

DN 118:161051

TI carbostyryl derivatives as apoptosis regulators for treatment of cancer and other diseases

IN Nakai, Satoru; Aihara, Koutoku; Mori, Hitomi; Tominaga, Michiaki; Adachi, Masakazu; Ichikawa, Hiroyuki; Akamatsu, Seiji; Saito, Fumio

PA Otsuka Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DT Patent

LA Japanese


IC ICM A61K031-495

CC 1-6 (Pharmacology)

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9300902	A1	19930121	WO 1992-JP841	19920702
	W: AU, CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	AU 9222317	A1	19930211	AU 1992-22317	19920702
	AU 648690	B2	19940428		
	EP 552373	A1	19930728	EP 1992-914177	19920702 <--

EP 552373 B1 19991013
 R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE
 JP 2628106 B2 19970709 JP 1992-502141 19920702
 ES 2138971 T3 20000201 ES 1992-914177 19920702
 US 5543412 A 19960806 US 1995-469893 19950606
 US 5658912 A 19970819 US 1995-469922 19950606
 US 5672603 A 19970930 US 1995-466449 19950606
 US 5750529 A 19980512 US 1995-469505 19950606
 US 5798356 A 19980825 US 1997-853746 19970509
 US 5872120 A 19990216 US 1997-854074 19970509
 US 5916890 A 19990629 US 1997-854073 19970509
 PRAI JP 1991-162587 19910703
 JP 1992-33469 19920220
 JP 1992-45718 19920303
 JP 1992-100585 19920325
 WO 1992-JP841 19920702
 US 1993-989028 19930430
 US 1995-466449 19950606
 OS MARPAT 118:161051
 GI



AB Carbostyryl derivs. I (R = benzoyl group having lower alkoxy substituents on the Ph ring) or salts thereof are apoptosis regulators effective in treating cancer and other diseases. For example, 6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-3,4-dihydrocarbostyryl at 10.mu.g/mL inhibited the growth of leukemia cells in cultures.
 ST carbostyryl deriv apoptosis regulator cancer; neoplasm inhibitor
 carbostyryl deriv
 IT Neoplasm inhibitors
 Virucides and Virustats
 (carbostyryl derivs.)
 IT Autoimmune disease
 (treatment of, carbostyryl derivs. for)
 IT Cell aging
 (apoptosis, regulators of, carbostyryl derivs. as)
 IT Blood platelet
 (disease, thrombocytopenia, treatment of, carbostyryl derivs. for)
 IT 81839-51-2 81839-94-3 81840-00-8 81840-15-5 81840-21-3
 81849-95-8 81922-74-9 146583-13-3
 RL: BIOL (Biological study)
 (as apoptosis regulator, for cancer and other disease treatment)

=> fil wpix

FILE 'WPIX' ENTERED AT 11:06:56 ON 13 JUN 2001
 COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE LAST UPDATED: 07 JUN 2001 <20010607/UP>
 MOST RECENT DERWENT UPDATE 200131 <200131/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> SDI'S MAY BE RUN ON EVERY UPDATE OR MONTHLY AS OF JUNE 2001.

(EVERY UPDATE IS THE DEFAULT). FOR PRICING INFORMATION
SEE HELP COST <<<

>>> FOR UP-TO-DATE INFORMATION ABOUT THE DERWENT CHEMISTRY
RESOURCE, PLEASE VISIT
<http://www.derwent.com/chemistryresource/index.html> <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
SEE <http://www.derwent.com/covcodes.html> <<<

=> d all abeq tech tot

L201 ANSWER 1 OF 9 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 2001-258083 [26] WPIX

DNC C2001-077836

TI Use of a composition comprising Mycobacterium phlei-DNA (M-DNA) for the
manufacture of medicament to disrupt mitochondrial function in cells to
treat e.g. cancer and autoimmune disorders.

DC B04 D16

IN FILION, M C; PHILLIPS, N C

PA (BION-N) BIONICHE LIFE SCI INC

CYC 94

PI WO 2001022979 A1 20010405 (200126)* EN 23p A61K035-74

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

ADT WO 2001022979 A1 WO 2000-CA1130 20000928

PRAI US 1999-156578 19990929

IC ICM A61K035-74

ICS **A61K031-70**; A61K047-48; A61P035-00; A61P037-00

AB WO 200122979 A UPAB: 20010515

NOVELTY - Use of a composition comprising Mycobacterial phlei (M.
phlei)-DNA (M-DNA) for the manufacture of a medicament to disrupt
mitochondrial function in cells in the animal, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for use
of a composition comprising M-DNA:M. phlei cell wall (MCC) for the
manufacture of a medicament to disrupt function in cells in the animal.

ACTIVITY - Antiapoptotic; antiproliferative; antiarthritic;
antirheumatic; antidiabetic; antiinflammatory; cytostatic; neuroprotective

Mice were divided into 5 groups. At time 0, the mice in each group
received the following: group 1, saline; group 2, MCC in saline; group 3,
M-DNA in saline; group 4, Dnase I treated MCC in saline; and group 5,
M-DNA in saline. After 2 hours, inflammation was induced in each mouse by
the injection of 0.5 ml of a 1% **carrageenan** solution into one
hind footpad. Footpad swelling was quantified by measuring
water-displacement at 0, 3, 6, 24, 48, 72 and 96 hours after
carrageenan administration. Groups 2, 3, and 6 mice had less
footpad inflammation than groups 1, 4 and 5 mice.

MECHANISM OF ACTION - Mitochondria inhibitor.

USE - M-DNA and MCC are useful for induction of **apoptosis**
and inhibition of proliferation, cells include cancer cells and cells
implicated in autoreactive, inflammatory and proliferative disorders.
Cancer cells include leukemia and breast cancer, autoreactive disorders
include multiple sclerosis, rheumatoid arthritis, insulin dependent
diabetes mellitus and myasthenia gravis, inflammatory disorders included
both acute and chronic inflammation and proliferative disorders include
myointimal hyperplasia and T-small lymphocyte disorder.

ADVANTAGE - The use of a composition comprising Mycobacterial phlei
(M. phlei)-DNA (M-DNA) is more advantageous than current therapeutic
agents to treat disorders that involve aberrant accumulation of unwanted
cells, because the composition does not require immune mediators for its
activity, it is simple and relatively inexpensive to prepare, its activity

remains therapeutically stable over time and it is effective at dose regimens that are associated with minimal toxicity even upon repeated administration.

Dwg.0/11

FS CPI

FA AB; DCN

MC CPI: B04-E03; B04-F10B2; B14-C03; B14-C09B; **B14-H01**; B14-H01B; B14-J01; B14-S04; D05-H04; D05-H12A

TECH UPTX: 20010515

TECHNOLOGY FOCUS - BIOLOGY - Preferred Method: The disruption of mitochondrial function is selected from the disruption of mitochondrial membrane potential, release of cytochrome c into the cytosol and inhibition of the mitochondrial electron transport chain from cytochrome c to cytochrome oxidase. The disruption of mitochondrial function induces a response selected from upregulation of Bax protein expression, degradation of procaspases, activation of caspases, cleavage of cellular substrate targets of activated caspases and release of NuMA, culminating in the inhibition of cell proliferation and the induction of cell **apoptosis**. The cells used are either cancer cells, or cells implicated in autoreactive disorders, inflammatory disorders or proliferative disorders.

L201 ANSWER 2 OF 9 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1999-460973 [39] WPIX

DNC C1999-135551

TI Poly-, oligo-, and mono- saccharides used to modulate **apoptosis** - can be used in the treatment of AIDS, cancer and auto-immune diseases.

DC A96 B04

IN ARRIGO, P; CLOAREC, B; CRUZ, F; DESCAMPS, V; RICHARD, C; THIBAL, V; YVIN, J C; YVIN, J

PA (GOEM-N) LAB GOEMAR SA

CYC 84

PI FR 2774289 A1 19990806 (199939)* 26p A61K031-70 <--

WO 9939718 A1 19990812 (199940) FR A61K031-70 <--

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL

OA PT SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD

GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV

MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT

UA UG US UZ VN YU ZW

AU 9921710 A 19990823 (200005) A61K031-70 <--

EP 1052996 A1 20001122 (200061) FR A61K031-70 <--

R: DE ES FR GB GR IT NL PT

ADT FR 2774289 A1 FR 1998-1237 19980203; WO 9939718 A1 **WO 1999-FR229**

19990203; AU 9921710 A AU 1999-21710 19990203; EP 1052996 A1 EP

1999-901702 19990203, **WO 1999-FR229 19990203**

FDT AU 9921710 A Based on WO 9939718; EP 1052996 A1 Based on WO 9939718

PRAI FR 1998-1237 19980203

IC ICM **A61K031-70**

ICS **A61K031-715; A61K031-725; A61K035-80**

AB FR 2774289 A UPAB: 19990928

NOVELTY - Medicine comprising, as active ingredient, a substance to modulate disturbances of **apoptosis**.

ACTIVITY - The active ingredients modulate disturbances of **apoptosis**.

MECHANISM OF ACTION - (I9) inhibits Fas **apoptosis**. (L11) potentiates Fas **apoptosis**.

USE - Use to treat disturbances of **apoptosis** is claimed.

(I9) can be used for the treatment of AIDS. (L11) can be used for the treatment of cancer and auto-immune diseases.

ADVANTAGE - None given.

Dwg.0/12

FS CPI

FA AB; GI; DCN

MC CPI: A12-V01; B04-C02D; B04-C02X; B10-A07; **B14-G01B; B14-G02D; B14-H01**

TECH

UPTX: 19990928

TECHNOLOGY FOCUS - PHARMACEUTICALS - The active ingredient is at least one polysaccharide, oligosaccharide, or monosaccharide, optionally substituted on one or more of its unit motifs by one or more of sulfate, methyl, and acetyl. The oligosaccharides are derived from 1-3 beta **glucans**, optionally with 1-6 beta branches, or from sulfated galactanes, notably **carrageenans**, **agars**, and **porphyranes**. The oligosaccharide is preferably of formula (I):
 $n = 1 - 50$, preferably $5 - 10$;
 the number of branches is $0 - 3$ per unit of repetition.
 The disaccharide is preferably of formula (II):
 $m = 1 - 50$, preferably $1 - 20$;
 the units of repetition can carry one or more sulfate groups.

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preparation: The active ingredient is prepared by:

(1) hydrolysis of sodium **iota-carrageenate**, which consists of a mixture of oligo-**iota-carrageenanes** (I9); the total -oses form 62% and the distribution is:
 (i) **ota-neocarra-tetraose** (6-8%),
 (ii) **hexaose** (23-27%),
 (iii) **octaose** (18-22%),
 (iv) **decaose** (12-18%),
 (v) **dodecaose** (11-15%),
 (vi) and oligo-**iota-carrageenanes** consisting of 7-15 disaccharides of repetition (18-22%).
 (2) aqueous acid extraction from brown algae, particularly *Laminaria digitata*, which gives a mixture of 1-3 beta **glucans** (L11) with 1-50, preferably 20-30 saccharidic units.

L201 ANSWER 3 OF 9 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1999-337690 [28] WPIX

DNC C1999-099294

TI Compositions comprise 3,6-anhydrogalactopyranose derivative.

DC B02 D13 D21 E13

IN ENOKI, T; IKAI, K; KATO, I; KOYAMA, N; NISHIYAMA, E; SAGAWA, H; SAKAI, T; TOMINAGA, T; YU, F

PA (TAKI) TAKARA SHUZO CO LTD

CYC 83

PI WO 9924447 A1 19990520 (199928)* JA 132p C07H003-10

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SZ UG ZWW: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD
GE GH GM HR HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG
MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG
US UZ VN YU ZW

AU 9910517 A 19990531 (199941) C07H003-10

EP 1038879 A1 20000927 (200048) EN C07H003-10

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

CN 1285838 A 20010228 (200131) C07H003-10

ADT WO 9924447 A1 WO 1998-JP5065 19981111; AU 9910517 A AU 1999-10517
19981111; EP 1038879 A1 EP 1998-953005 19981111, WO 1998-JP5065 19981111;
CN 1285838 A CN 1998-813026 19981111

FDT AU 9910517 A Based on WO 9924447; EP 1038879 A1 Based on WO 9924447

PRAI JP 1998-212041 19980713; JP 1997-323917 19971111; JP 1998-20146

19980119; JP 1998-130973 19980427; JP 1998-164410 19980529

IC ICM C07H003-10

ICS A01N001-00; A01N003-00; A23L001-30; A23L003-3544; A23L003-3562;

A61K031-70; A61K031-725; C07H011-00; C08B037-00;

C08B037-12; C09K015-06

AB WO 9924447 A UPAB: 19990719

NOVELTY - Medicinal compositions comprise (i) a 3,6-anhydrogalactopyranose (I) or its aldehyde, hydrate or 2-O-methylated derivatives or (ii) a soluble sugar compound containing (i).

DETAILED DESCRIPTION - Medicinal compositions comprise (i) a 3,6-anhydrogalactopyranose (I) of formula (I)

or its aldehyde, hydrate or 2-O-methylated derivatives or (ii) a soluble sugar compound containing (i).

INDEPENDENT CLAIMS are also included for foods, drinks, cosmetics and antioxidants comprising (i) or (ii).

ACTIVITY - Cytostatic. In assays agarobiose had the following IC50 values (no units given) HL-60 (32), Hep2 (8), A-172 (16) and HeLa S3 (8).

MECHANISM OF ACTION - Antioxidant

USE - For inducing **apoptosis**, as active oxygen, lipid peroxide radical and NO radical production inhibitors useful as carcinostatics, antioxidants and preservatives.

ADVANTAGE - The agents have low toxicity and are extracted from natural products (especially algae).

Dwg.0/42

FS CPI

FA AB; GI; DCN

MC CPI: B06-A02; **B14-H01**; B14-S08; D03-H01P; D03-H02E; D08-B; E06-A02E

TECH UPTX: 19990719

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Composition: The composition also comprises agar, agarose and/or **carragenan**

L201 ANSWER 4 OF 9 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1998-322663 [28] WPIX

DNC C1998-099288

TI Butyric ester(s) of poly saccharide(s) for treatment of tumours, etc. - combine anti-proliferative activity of both moieties and improve bio-availability of the butyric residue.

DC A96 B04 B05

IN CORADINI, D; PERBELLINI, A

PA (RICE-N) SOC COOP CENT RICERCHIE POLY-TECH A RESPO; (CORA-I) CORADINI D; (PERB-I) PERBELLINI A

CYC 80

PI WO 9823648 A1 19980604 (199828)* EN 34p C08B037-00

RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AU 9857515 A 19980622 (199844) C08B037-00

EP 941253 A1 19990915 (199942) EN C08B037-00

R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE SI

IT 1286510 B 19980715 (200053) C12P000-00

US 6140313 A 20001031 (200057) A61K031-72

JP 2001505940 W 20010508 (200131) 34p C08B037-00

ADT WO 9823648 A1 WO 1997-EP6589 19971126; AU 9857515 A AU 1998-57515 19971126; EP 941253 A1 EP 1997-953702 19971126; WO 1997-EP6589 19971126; IT 1286510 B IT 1996-MI2505 19961129; US 6140313 A WO 1997-EP6589 19971126; US 1999-308832 19990525; JP 2001505940 W WO 1997-EP6589 19971126; JP 1998-524276 19971126

FDT AU 9857515 A Based on WO 9823648; EP 941253 A1 Based on WO 9823648; US 6140313 A Based on WO 9823648; JP 2001505940 W Based on WO 9823648

PRAI IT 1996-MI2505 19961129

IC ICM A61K031-72; C08B037-00; C12P000-00

ICS **A61K031-715**; A61P019-00; A61P035-00; A61P043-00

AB WO 9823648 A UPAB: 19980715

Butyric esters (I) of polysaccharides, where the hydroxyl groups are partially or totally esterified with butyric residues and any free hydroxyl groups of the glycosidic residue are optionally esterified with dicarboxylic acid residues, are new.

The polysaccharides are substituted on the carbon atoms of the glycosidic ring by at least 1 group selected from: lower alkyl, NH2, NHCOR, OSO3H, OPO3H2, COOH, COO(CH2)nCOOH, COOR, OR and O(CH2)nOCOR9 (n = 1-4 and R = 1-10C alkyl). Free hydroxyls on the glycosidic residue are esterified with at least 1 of 2-9C dicarboxylic acids selected from succinic, tartaric, malic and azelaic acids. (I) contain 0.001-3.0

(preferably 0.01-1.0) hydroxyls esterified with butyric residues per glycosidic monomer and have an average molecular weight of 1×10^4 to 5×10^6 . The polysaccharide is a neutral **glucan** containing beta -(1 => 3) and beta -(1 => 6)-glucosidic residues, especially **scleroglucan** or is an anionic polysaccharide containing sulphated and/or carboxylic groups. Preferred anionic polysaccharides include hyaluronic acid, alginic acid, pectin, heparins, heparinoids, **carrageenans** and polysaccharide isolated from Grateloupia doryphora.

USE - (I) combine the known antiproliferative activities of polysaccharides and butyric acid to provide a stable pharmaceutical with a more durable half-life than that of the butyric acid derivatives of the prior art. Both the polysaccharide and the butyric acid moieties are naturally occurring products with anti-proliferative activity and low toxicity. (I) are suitable for the treatment of tumours and conditions susceptible to neoplastic degeneration e.g. inflammatory intestinal diseases, diverticulosis, Crohn's disease and colitis. Similarly (I) can be used to treat disorders caused by synovial cell proliferation and other abnormal cell proliferation e.g. rheumatoid arthritis, psoriasis, hyperkeratosis and prostate hyperplasia. Administration is oral, parenteral, topical or transdermal. Dosage is 0.2-500 mg/kg/day for 1-15 days.

Dwg.0/0

FS CPI

FA AB

MC CPI: A03-A; A10-E07; A12-V01; B04-C02; B14-H01

L201 ANSWER 5 OF 9 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1998-172064 [16] WPIX

DNC C1998-055104

TI Cancer therapeutic immune food - comprises U-fucoidan, D-fraction, beta-**glucan**, organic germanium and polysaccharide(s).

DC B04 D13

PA (MATO-I) MATOBA J; (SOGA-I) SOGABE T

CYC 1

PI JP 10033142 A 19980210 (199816)* 4p A23L001-30

ADT JP 10033142 A JP 1996-225814 19960724

PRAI JP 1996-225814 19960724

IC ICM A23L001-30

ICS A61K031-28; A61K031-555; **A61K031-715; A61K035-80;**
A61K035-84

AB JP 10033142 A UPAB: 19980421

Cancer therapeutic immune food is composed of combinations of several components with different pharmaceutical effects for synergism and acceleration of **apoptosis** and eradication of cancer cells containing U-fucoidan, D-fraction, beta -**glucan**, an organic germanium, and other polysaccharides.

Dwg.0/3

FS CPI

FA AB; DCN

MC CPI: B04-C02; B05-A02; **B14-H01**; B14-S09; D03-H01T2

L201 ANSWER 6 OF 9 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1995-082546 [12] WPIX

DNC C1995-037177

TI New water insoluble, cation complexed anionic polysaccharide(s) - used to treat diarrhoea and wt. loss, partic. added to liq. nutritional compsn. as source of dietary fibre, to improve intestinal function without increasing prod. viscosity.

DC A11 A96 B04 C03 D13 D17

IN BARNUM, P E; MAJEWICZ, T G

PA (HERC) HERCULES INC

CYC 23

PI AU 9467502 A 19950127 (199512)* 57p C08B037-06

NO 9402620 A 19950117 (199512) EN C08B037-00

CA 2128160 A 19950117 (199516) C08B037-00

FI 9403296 A 19950117 (199516) C08B037-00
 EP 648495 A2 19950419 (199520) EN 35p A61K031-715 <--
 R: AT BE CH DE DK ES FR GB IT LI NL PT SE
 JP 07090002 A 19950404 (199522) 26p C08B037-00
 BR 9402851 A 19950613 (199530) A61K038-16
 CZ 9401702 A3 19951018 (199549) C08B037-00
 EP 648495 A3 19950809 (199613) C08B037-06
 NZ 260933 A 19960726 (199635) A23L001-052
 AU 675542 B 19970206 (199714) C08B037-06
 CN 1104890 A 19950712 (199729) A61K031-715 <--
 HU 75240 T 19970528 (199803) A61K031-715 <--
 EP 648495 B1 20000105 (200006) EN A61K031-715 <--
 R: AT BE CH DE DK ES FR GB IT LI NL PT SE
 DE 69422465 E 20000210 (200015) A61K031-715 <--
 ES 2140482 T3 20000301 (200018) A61K031-715 <--
 ADT AU 9467502 A AU 1994-67502 19940715; NO 9402620 A NO 1994-2620 19940712;
 CA 2128160 A CA 1994-2128160 19940715; FI 9403296 A FI 1994-3296 19940711;
 EP 648495 A2 EP 1994-111053 19940715; JP 07090002 A JP 1994-163665
 19940715; BR 9402851 A BR 1994-2851 19940718; CZ 9401702 A3 CZ 1994-1702
 19940714; EP 648495 A3 EP 1994-111053 19940715; NZ 260933 A NZ 1994-260933
 19940705; AU 675542 B AU 1994-67502 19940715; CN 1104890 A CN 1994-116163
 19940716; HU 75240 T HU 1994-2102 19940714; EP 648495 B1 EP 1994-111053
 19940715; DE 69422465 E DE 1994-622465 19940715, EP 1994-111053 19940715;
 ES 2140482 T3 EP 1994-111053 19940715
 FDT AU 675542 B Previous Publ. AU 9467502; DE 69422465 E Based on EP 648495;
 ES 2140482 T3 Based on EP 648495
 PRAI US 1993-93231 19930716
 REP No-SR.Pub; EP 191572; EP 29724; EP 40048; EP 483070; EP 506563; FR
 2073254; FR 7686; US 3474086; US 5104677; WO 8704350; WO 9104674; WO
 9319613; WO 9325096
 IC ICM A23L001-052; A61K031-715; A61K038-16; C08B037-00;
 C08B037-06
 ICS A23L001-0524; A23L001-0526; A23L001-29; A23L001-305; A23L001-308;
 A23L001-48; A23L002-52; A61K009-10; A61K031-195; A61K031-70
 ; A61K031-725; A61K031-74; A61K038-00; C08B011-00;
 C08B011-12; C08B015-00; C08B031-00; C08B031-12; C08B037-04;
 C08L001-08; C08L003-04; C08L005-00
 ICI A61K031-725, A61K031:195, A61K033:06, A61K033:14; A61K031-725, A61K033:06,
 A61K033:14
 AB AU 9467502 A UPAB: 19950328
 Water-insoluble, cation-complexed anionic polysaccharides (I) are new.
 The cation is at least one alkali, alkaline earth or transition
 metal, esp. Ca, Fe, Mg, Zn, K, Na, Al, Cu and/or Mn.
 The polysaccharide is (a) carboxylated, i.e. an alginate, pectin, gum
 (arabic, karaya, tragacanth, ghatti, psyllium, xanthan or gellan),
 flaxseed, okra, carboxymethylated cellulose, guar or starch, or hyaluronic
 acid; (b) sulphated, i.e. carrageenan, heparin, keratan or
 chondroitin, dermatan, heparin, keratan or cellulose sulphates, or (c)
 phosphorylated cellulose, starch or glucan. Partic. the
 polysaccharide is a pectin of methyl or acetyl esterification below 5 %
 and degree of polymerisation over 150, esp. complexed with Ca at mole
 ratio Ca; anhydrogalacturonic acid 0.1-0.6.
 USE - (I) have an antidiarrhoeal effect in humans and other animals,
 partic. in subjects who have undergone surgery for removal of part of the
 gastrointestinal tract, but also in e.g. diabetes, cardiovascular disease,
 cancer, AIDS etc. They can also be used to treat wt. loss.
 Partic. (I) are incorporated into foods (e.g. liq. feeding compsns.)
 or pharmaceutical compsns.
 ADVANTAGE - (I) is a source of dietary fibre that can be incorporated
 into liq. or solid feeding compsns. for oral or enteral delivery. It
 improves gastrointestinal function (nutrient and water absorption) without
 increasing the viscosity of liq. formulations (even after heat
 sterilisation) and with no significant effect on flavour, colour or
 coagulation behaviour.
 Dwg.0/0
 FS CPI

FA AB; DCN
 MC CPI: A03-A01; A12-V01; B04-C02A; C04-C02A; B04-C02B; C04-C02B; B04-C02D;
 C04-C02D; B04-C02E; C04-C02E; B14-E02; C14-E02; D03-H01T1; D06-H

L201 ANSWER 7 OF 9 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1994-082796 [10] WPIX

DNN N1994-064763 DNC C1994-037859

TI Treating or preventing irritable bowel syndrome - by orally administering
 an anion-binding and hydrophilic polymer eg colestipol and pectin.

DC A96 B04 P34

IN DAY, C E

PA (DAYC-I) DAY C E

-CYC 43

PI WO 9404136 A1 19940303 (199410)* EN 27p A61K009-58

RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA PT SE

W: AU BB BG BR CA CZ FI HU JP KP KR LK MG MN MW NO NZ PL RO RU SD SK

UA

AU 9347978 A 19940315 (199428) A61K009-58

US 5380522 A 19950110 (199508) 6p A61K031-74

EP 654992 A1 19950531 (199526) EN A61K009-58

R: DE FR GB NL

CN 1085084 A 19940413 (199527) A61K031-725 <--

AU 667955 B 19960418 (199623) A61K031-74

IL 106640 A 19970415 (199726) A61K047-00

ADT WO 9404136 A1 WO 1993-US7242 19930802; AU 9347978 A AU 1993-47978
 19930802; US 5380522 A US 1992-928509 19920811; EP 654992 A1 EP
 1993-918568 19930802, WO 1993-US7242 19930802; CN 1085084 A CN 1993-116222
 19930811; AU 667955 B AU 1993-47978 19930802; IL 106640 A IL 1993-106640
 19930810

FDT AU 9347978 A Based on WO 9404136; EP 654992 A1 Based on WO 9404136; AU
 667955 B Previous Publ. AU 9347978, Based on WO 9404136

PRAI US 1992-928509 19920811

REP 1.Jnl.Ref; US 3579634; US 3627872; US 3974272; US 4172120; US 4303638; US
 4895723; US 4999341; US 5026555; US 5102664; US 5112856; US 5213806

IC ICM A61K009-58; **A61K031-725**; A61K031-74; A61K047-00

ICS A01N043-04; A61K009-68; A61K031-35; A61K031-47; **A61K031-70**;

A61K031-715; A61K031-785; A61K039-02; A61L009-04

AB WO 9404136 A UPAB: 19940421

An orally ingestible pharmaceutical compsn. consists of a dry powdered
 admixture of an anion-binding polymer and a hydrophilic polymer, or a
 polymer which is both an anion-binding polymer and a hydrophilic polymer,
 opt. together with a suitable diluent or carrier. A method of treating or
 preventing irritable bowel syndrome, including diarrhoea, constipation and
 pain associated with the syndrome, in a human, consists essentially of
 orally administering an anion-binding polymer and a hydrophilic polymer
 either simultaneously, concurrently or in the above form.

The anion-binding polymer is pref. cholestyramine, a colestipol
 acid-addition salt MCI-196 or diethylaminoethyl dextran and the
 hydrophilic polymer is pectin, guar gum, psyllium hydrophilic colloid,
 locust bean gum, alginic acid, cellulose gum, **carrageenan**, oat
 bran beta-glutan, xanthan gum, methylcellulose or polycarbophil, pref.
 respectively cholestyramine or a colestipol salt and pectin, or the two
 characteristics are combined in a single polymer, esp. chitosan.

The total amt. of polymer per dose of the compsn. is suitably 1-24g.

Dwg.0/0

FS CPI GMPI

FA AB; DCN

MC CPI: A12-V01; B04-C02; B04-C03B; B14-E02; B14-E10

ABEQ US 5380522 A UPAB: 19950301

Treating irritable bowel syndrome including diarrhoea, constipation and
 pain or their symptoms in humans comprises oral admin of an anion-binding
 polymer (ABP) and a hydrophilic polymer (HP) simultaneously or
 concurrently or in the form of a compsn.

Pref the wt. ratio of ABP to HP is 2:1 to 1:2 ABP is eg
 cholestyramine cholestypol or diethylamino dextran and HP is e.g. pectin,
 psyllium hydrophilic colloid, cellulose gum, alginate acid, methyl

cellulose, polycarbophil, locust bean gum, carrogeenan, xanthan gum or oat bran beta-**glucan**.

ADVANTAGE - There was previously no effective treatment for irritable bowel syndrome.
Dwg.0/0

L201 ANSWER 8 OF 9 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1993-182688 [22] WPIX
CR 1991-325347 [44]; 1994-150866 [18]
DNN N1993-140406 DNC C1993-080972
TI Contrast medium for diagnostic imaging - comprises gel particles of less than 90 microns in mean dia. and which comprise a polymer entrapping a contrast enhancing metal.
DC A96 B04 P31 S03 S05
IN UNGER, E C
PA (UNGE-I) UNGER E C; (IMAR-N) IMARX PHARM CORP
CYC 20
PI WO 9310440 A1 19930527 (199322)* EN 43p G01N024-08
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE
W: AU CA JP
AU 9228940 A 19930615 (199340) G01N024-08
EP 614527 A1 19940914 (199435) EN
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE
US 5358702 A 19941025 (199442) 13p A61B005-055
JP 07501331 W 19950209 (199515) A61K049-00
AU 667491 B 19960328 (199622) A61K049-04
US 5976500 A 19991102 (199953) A61B005-055
ADT WO 9310440 A1 WO 1992-US8948 19921020; AU 9228940 A AU 1992-28940 19921020; EP 614527 A1 EP 1992-922870 19921020; WO 1992-US8948 19921020; US 5358702 A CIP of US 1990-507125 19900410, Cont of US 1991-794437 19911119, US 1993-62325 19930514; JP 07501331 W WO 1992-US8948 19921020, JP 1993-509251 19921020; AU 667491 B AU 1992-28940 19921020; US 5976500 A CIP of US 1990-507125 19900410, Cont of US 1991-794437 19911119, Div ex US 1993-62325 19930514, US 1994-285977 19940804
FDT AU 9228940 A Based on WO 9310440; EP 614527 A1 Based on WO 9310440; JP 07501331 W Based on WO 9310440; AU 667491 B Previous Publ. AU 9228940, Based on WO 9310440; US 5976500 A Div ex US 5358702
PRAI US 1991-794437 19911119; US 1990-507125 19900410; US 1993-62325 19930514; US 1994-285977 19940804
REP US 4452773; US 4692325; US 4735796; US 4749560; US 4863715; US 4985233; US 5128121; US 5160725
IC ICM A61B005-055; A61K049-00; A61K049-04; G01N024-08
ICS A61K009-16; **A61K031-715**; A61K047-30
AB WO 9310440 A UPAB: 19991215
Contrast medium comprises gel particles of less than 90 microns in mean diameter. The gel particles comprise a polymer entrapping a contrast enhancing metal.

Also claimed are (1) a contrast medium of gel particles which comprise a non-crosslinked polymer entrapping a contrast enhancing metal; (2) a method of providing an image of an internal region of a patient, or for diagnosing the presence of diseased tissue in a patient, comprises: (i) administering to the patient a contrast medium as described in (A) or (B) above, and (ii) scanning the patient using magnetic resonance imaging, ultrasound imaging X-ray imaging to obtain visible images of the region or of any diseased galacturonans, **glucans**, mannans, xylans, levan, fucoidan, **carrageenan**, galactocarolose, pectins, pectic acids, amylose, pullulan, glycogen, amylopectin, cellulose, dextran, pustulan, chitin, agarose, keratin, chondroitin, dermatan, hyaluronic acid, alginic acid, xanthan gum, starch, carboxymethyl cellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, methylcellulose, methoxycellulose, and polysaccharides contg. an aldose, ketose, acid or amine selected from erythrose, threose, ribose, arabinose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, galactose, tabose, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, glucuronic acid, gluconic acid, **glucanic** acid, galacturonic acid, mannuronic acid, glucosaminic acid, galactosamine and neuraminic acid.

Pref. the polysaccharide is pectin which is a low methoxy pectin having phosphorylated 30% methoxylation, polygalacturonic acid or the polymer may be a phosphorylated polymer

Dwg.0/1

Dwg.0/1

FS CPI EPI GMPI

FA AB; DCN

MC CPI: A12-V03C2; A12-V03D; B04-C02; B04-C03B; B04-C03D; B05-A03; B11-C08A; B12-K04C; B12-K07; B12-M03

EPI: S03-E07A; S03-E09X; S05-D02B2

ABEQ US 5358702 A UPAB: 19941212

Pharmaceutically acceptable contrast medium comprises firm gel particles of less than 90 microns mean dia. The particles comprise at least one methoxylated natural or modified natural polymer entrapping contrast enhancing material.

Pref. dia. of gel particles in 5 nm- 90 micron (10-200)nm. Pref. polymer is a polysaccharide.

USE - As contrast medium for X-ray, ultra-sound and MRI imaging.
Dwg.0/1

L201 ANSWER 9 OF 9 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1982-89076E [42] WPIX

TI Hypoglycaemic compsn. for treating metabolic and digestive diseases - comprise difficult to digest polysaccharide(s), oligosaccharide(s) or their derivs..

DC B04 D16

PA (ENDO-I) ENDO A

CYC 1

PI JP 57146713 A 19820910 (198242)* 4p

PRAI JP 1981-33513 19810309; JP 1983-186305 19810309

IC A61K031-70; C07H003-06

AB JP 57146713 A UPAB: 19930915

Hypoglycemics contain, as active ingredient, saccharides selected from hardly digestable polysaccharides, oligosaccharides and their derivs., which are pref. those produced by microorganisms or those obtd. from vegetables or animals.

Hardly digestable polysaccharides of microorganism origin include **alpha-glucans** (e.g. dextran, erucinan), **beta-glucans** (e.g. cellulose, sclerotan), and polysaccharides produced by bacteria of the genus Azotobacter, Pseudomonas, Rhinocladiella, Cryptococcus, etc. Hardly digestable polysaccharides of vegetable or animal origin include cellulose, hydroxyethyl starch, mannan, pectin, guar gum, **carragheenin**, chitosan, etc. Hardly digestable oligosaccharides of bacterium origin include alpha-, beta- and gamma-cyclodextrin, isomaltotriose, isomaltotetrose, isomaltopentose, etc.

Acute toxicity at least 500 mg/Kg (p.o.) Dosage is 0.1-10 g/day, pref. 0.2-5 g/day, orally.

FS CPI

FA AB

MC CPI: B04-C02; B12-H05; B12-J01; D06-H

=>

=>

=> d his

(FILE 'HOME' ENTERED AT 09:26:49 ON 13 JUN 2001)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 09:27:03 ON 13 JUN 2001
E WO99-FR229/AP,PRN

L1 1 S E3,E4
E FR99-1237/AP,PRN

L2 1 S E3,E4
E FR98-1237/AP,PRN

L3 1 S L1,L2
 E YVIN J/AU
 L4 37 S E4,E5
 E CRUZ F/AU
 L5 77 S E3-E12,E31
 E DESCAMPS V/AU
 L6 10 S E3,E4
 E RICHARD C/AU
 L7 202 S E3-E15,E39-E40
 E THIBAL V/AU
 L8 1 S E4
 E ARRIGO P/AU
 L9 11 S E3,E4
 E CLOAREC B/AU
 L10 5 S E4
 E GOEMAR/PA,CS
 L11 33 S E3-E9
 L12 334 S L4-L11
 L13 1 S L3 AND L12
 E APOPTOSIS/CW
 L14 30798 S E3
 E APOPTOSIS/CT
 E E3+ALL
 L15 1048 S E5
 L16 43760 S E4/BI,CT
 E E3+ALL
 L17 34377 S E3+NT
 L18 1483 S E4
 L19 17461 S E9+NT OR E8+NT OR E10+NT OR E11+NT OR E12+NT
 L20 62340 S L14-L19
 L21 3 S L12 AND L20
 L22 1 S L21 AND ?SACCHARID?
 L23 1 S L13,L22
 L24 23 S L12 AND ?SACCHARID?
 L25 6 S L12 AND CARBOHYDRATE#/SC, SX
 E SACCHARIDE/CW
 L26 1039 S E4
 E MONOSACCHARIDE/CW
 L27 6883 S E3,E4
 E DISACCHARIDE/CW
 L28 1103 S E4
 E TRISACCHARIDE/CW
 L29 234 S E4
 E POLYSACCHARIDE/CW
 L30 32500 S E3,E4
 E OLIGOSACCHARIDE/CW
 L31 22161 S E3,E4
 E OLIGOSACCHARIDE/CT
 E E9+ALL
 L32 1040 S E4,E5
 L33 122473 S E3+NT
 L34 174616 S ?SACCHARID?
 L35 4891 S BETA(2W) GLUCAN
 L36 3 S IOTA()NEOCARRATETRAOSE
 L37 3 S IOTA()NEOCARRAHEXAOSE
 L38 1 S IOTA()NEOCARRAOCTAOSE
 L39 1 S IOTA()NEOCARRADECAOSE
 L40 1 S IOTA()NEOCARRADODECAOSE
 L41 763 S IOTA()CARRAGEENAN
 L42 0 S OLIGO(L) IOTA()CARRAGEENAN
 L43 1 S OLIGO(L) IOTA(L)CARRAGEENAN
 L44 6 S OLIGO(L)CARRAGEENAN
 L45 11 S NEOCARRATETRAOSE OR NEOCARRAHEXAOSE OR NEOCARRAOCTAOSE OR NEO
 L46 0 S NEO(L) (CARRATETRAOSE OR CARRAHEXAOSE OR CARRAOCTAOSE OR CARRA
 L47 12 S ?CARRATETRAOSE OR ?CARRAHEXAOSE OR ?CARRAOCTAOSE OR ?CARRADEC
 L48 12 S ?CARRATETRAOS? OR ?CARRAHEXAOS? OR ?CARRAOCTAOS? OR ?CARRADEC

FILE 'REGISTRY' ENTERED AT 09:42:08 ON 13 JUN 2001

L49 1 S 9062-07-1
L50 5 S 237069-70-4 OR 237069-74-8 OR 237069-76-0 OR 237069-79-3 OR 2
L51 0 S (237069-70-4 OR 237069-74-8 OR 237069-76-0 OR 237069-79-3 OR

FILE 'HCAPLUS' ENTERED AT 09:43:45 ON 13 JUN 2001

L52 1 S L50
L53 12 S L36-L40,L45,L47,L48,L52
L54 1 S L53 AND L20
L55 2 S L53 AND L35
L56 4 S L53 AND L41
L57 5 S L23,L54-L56
L58 1 S L57 AND (1 OR 63)/SC,SX

FILE 'REGISTRY' ENTERED AT 09:47:51 ON 13 JUN 2001

L59 1 S 11016-36-7
L60 1 S 9002-18-0
L61 1 S 9000-07-1
L62 1 S 39475-64-4
E L-GALACTAN/CN
L63 1 S E3
E D-GALACTAN/CN
L64 1 S E3
E DL-GALACTAN/CN
L65 2 S L63,L64
SEL RN
L66 7 S E1-E2/CRN
L67 1 S L66 AND H2O4S AND 2/NC

FILE 'HCAPLUS' ENTERED AT 09:49:52 ON 13 JUN 2001

L68 6986 S L59 OR L60 OR L61 OR L62 OR L67 OR L65
L69 47922 S CARRAGEENAN OR AGAR OR PORPHYRAN OR GALACTAN (A) (SULFATE? OR
L70 253 S L69 AND L20
L71 1 S L70 AND L53
L72 20 S L68 AND L20
L73 1 S L72 AND L53
L74 1 S L71,L73,L58
L75 940 S BETA 1 3 GLUCAN

FILE 'REGISTRY' ENTERED AT 09:55:08 ON 13 JUN 2001

L76 1 S 9051-97-2
L77 1 S 54724-00-4
E BETA.-DL-GLUCAN/CN
E BETA.-L-GLUCAN/CN
E BETA.-D-GLUCAN/CN
E .BETA.-D-GLUCAN/CN
L78 2 S E49
E .BETA.-DL-GLUCAN/CN
E .BETA.-L-GLUCAN/CN

FILE 'HCAPLUS' ENTERED AT 09:57:29 ON 13 JUN 2001

L79 1577 S L78
L80 5 S L79 AND L20
L81 3 S L80 AND APOPTO?
L82 2 S L80 AND CELL() (DEATH OR SURVIV? OR AGING OR AGEING)
L83 4 S L81,L82,L74
L84 5171 S BETA (3W) GLUCAN
L85 5171 S L75,L84
L86 1957 S L85 AND 1 3
L87 12 S L86 AND L20
L88 3 S L87 AND APOPTO?
L89 5 S L87 AND CYTOL?
L90 10 S L83,L88,L89
L91 2 S L90 AND (FUNGAL OR YEAST)/TI
L92 8 S L90 NOT L91

FILE 'REGISTRY' ENTERED AT 10:08:16 ON 13 JUN 2001
L93 1 S 9062-07-1

FILE 'HCAPLUS' ENTERED AT 10:08:34 ON 13 JUN 2001
L94 739 S L93
L95 763 S IOTA CARRAGEENAN
L96 854 S L94,L95
L97 3 S L20 AND L96
L98 27 S L20 AND L85
L99 10 S L92,L97
L100 2 S L99 NOT L92
L101 8 S L99 NOT L100
E FAS LIGAND/CT
E E3+ALL
L102 2086 S E6,E5+NT
E E10+ALL
L103 3739 S E7,E6+NT
L104 4371 S L102,L103
L105 1 S L104 AND L53
L106 1 S L104 AND L79,L85,L96
L107 8 S L101,L105,L106
L108 5715 S L79,L85
L109 5715 S BETA (S) GLUCAN
L110 6212 S L108,L109
L111 83 S L110 AND L68
L112 118 S L110 AND L69
L113 140 S L111,L112
L114 6 S L113 AND L96
L115 18 S L113 AND 63/SC,SX
L116 21 S L113 AND 1/SC,SX
L117 5 S L113 AND 15/SC,SX
L118 22 S L113 AND THU/RL
L119 38 S L115-L118
L120 35 S L119 AND (PY<=1999 OR PRY<=1999 OR AY<=1999)
L121 8 S L120 AND (ANTITUMOR OR SSG OR BRANCHED OR BOWEL OR CONFORMATI
L122 7 S L121 NOT BOWEL/TI
L123 15 S L92,L101,L107,L122

FILE 'REGISTRY' ENTERED AT 10:28:08 ON 13 JUN 2001
L124 1 S 9041-22-9

FILE 'HCAPLUS' ENTERED AT 10:28:18 ON 13 JUN 2001
L125 1 S L124 AND L123
L126 15 S L123,L125
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 10:29:02 ON 13 JUN 2001
L127 13 S E1-E13

FILE 'HCAPLUS' ENTERED AT 10:29:24 ON 13 JUN 2001
L128 43760 S L14-L16
L129 45691 S APOPTO?
L130 45691 S L128,L129
L131 18470 S L20 NOT L130
L132 54 S OLIGOSACCHARID? AND L130
L133 97 S OLIGOSACCHARID? AND L131
L134 150 S L132,L133 NOT L126
L135 128 S L134 AND (PY<=1999 OR PRY<=1999 OR AY<=1999)
L136 0 S L135 AND GLUCAN
L137 0 S L135 AND POLYGLUCAN
L138 1 S L135 AND ?CARRAGEEN?

FILE 'MEDLINE' ENTERED AT 10:31:58 ON 13 JUN 2001
E APOPTOSIS/CT
E E3+ALL

L139 34434 S E5+NT
 L140 42347 S E5,E7/BI
 E APOPTO
 L141 42333 S E37
 L142 16893 S E51
 L143 18 S E61-E63
 L144 44190 S L140-L143
 E OLIGOSACCHARIDE/CT
 E E5+ALL
 L145 44089 S E5+NT
 L146 241469 S E4+NT
 L147 1647 S BETA (3W) GLUCAN
 E GLUCANS/CT
 E E3+ALL
 L148 2464 S E5
 L149 2811 S E5/BI,CN
 L150 0 S L124
 L151 0 S L93
 L152 429 S L76-L78
 L153 0 S L49
 L154 0 S L50
 L155 8 S L36-L40,L43-L45,L48
 L156 797 S L144 AND L145-L155
 L157 13 S L156 AND ?GLUCAN?
 L158 9 S L157 AND PY<=1999

FILE 'HCAPLUS' ENTERED AT 10:40:43 ON 13 JUN 2001

FILE 'REGISTRY' ENTERED AT 10:41:25 ON 13 JUN 2001

FILE 'MEDLINE' ENTERED AT 10:42:00 ON 13 JUN 2001

FILE 'HCAPLUS' ENTERED AT 10:42:34 ON 13 JUN 2001

 E WO9502684/PN
 L159 2 S E3
 E EP0552373/PN
 L160 1 S E3
 E EP0795560/PN
 L161 1 S E3
 L162 4 S L159-L161 NOT L126

FILE 'HCAPLUS' ENTERED AT 10:44:25 ON 13 JUN 2001

FILE 'WPIX' ENTERED AT 10:45:42 ON 13 JUN 2001

 E WO99-FR229/AP,PRN
 L163 1 S E3
 L164 11411 S A61K031-70/IC
 L165 1747 S A61K031-715/IC
 L166 903 S A61K031-725/IC
 L167 499 S A61K035-80/IC
 L168 43 S L167 AND L164-L166
 E R24036+ALL/DCN
 L169 309 S E1
 E R24070+ALL/DCN
 L170 417 S E1
 E CARRAGEEN
 L171 2223 S E2,E5,E6,E8-E11
 L172 376 S E13-E21,E23,E24
 L173 24 S E25,E28-E36
 L174 110 S E39-E48
 L175 127 S E49-E60
 L176 35 S E61-E64,E66-E72
 L177 49 S E73-E80
 E CARAGE
 L178 1 S E4
 L179 2665 S ?CARRAGEEN?

L180 3048 S L169,L171-L179
L181 33 S L180 AND (GLUCAN OR POLYGLUCAN)
L182 1 S L181 AND ?NEOCARRA?

FILE 'WPIX' ENTERED AT 10:58:33 ON 13 JUN 2001

L183 1 S L181 AND (TETRAOSE OR ?HEXAOSE OR ?OCTAOSE OR ?DECAOSE OR ?DO
L184 1 S L181 AND PORPHYRAN?
L185 13 S L181 AND AGAR
L186 5 S L181 AND L170
L187 13 S L182-L186
L188 3 S APOPTO? AND L180
L189 147 S APOPTO? AND L164-L167
L190 2 S L189 AND (GLUCAN OR POLYGLUCAN)
L191 4 S L188,L190
L192 83 S L189 AND (B14-H01 OR C14-H01 OR B12-G07 OR C12-G07 OR B14-G01
L193 98 S L189 AND (P633 OR P434 OR P210)/M0,M1,M2,M3,M4,M5,M6
L194 2 S L192,L193 AND ?GLUCAN?
L195 4 S L163,L182,L191,L194
L196 4 S L195 AND L163-L194
L197 182 S ?GLUCAN? AND L164-L167
L198 6 S L197 AND L180
L199 5 S L198 NOT L196
L200 9 S L196,L198-L199
L201 9 S L200 AND L163-L199

FILE 'WPIX' ENTERED AT 11:06:56 ON 13 JUN 2001